



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07H 21/04, 21/02, C12N 15/11, 15/00,</b> <b>1/21, 15/63, C07K 14/00, A61K 38/00,</b> <b>C12P 19/34</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/26961</b> <b>(43) International Publication Date:</b> 3 June 1999 (03.06.99)
<b>(21) International Application Number:</b> PCT/US98/25149 <b>(22) International Filing Date:</b> 24 November 1998 (24.11.98)  <b>(30) Priority Data:</b> 60/066,804                      26 November 1997 (26.11.97)      US 09/197,886                      23 November 1998 (23.11.98)      US  <b>(71) Applicant:</b> GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).	<b>(72) Inventors:</b> JACOBS, Kenneth; 151 Beaumont Avenue, Newton, MA 02160 (US). MCCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LAVALLIE, Edward, R.; 113 Ann Lee Road, Harvard, MA 01451 (US). COLLINS-RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). EVANS, Cheryl; 307 Brighton Drive, Beverly, MA 01915 (US). MERBERG, David; 2 Orchard Drive, Acton, MA 01720 (US). TREACY, Maurice; 93 Walcott Road, Chestnut Hill, MA 02167 (US). AGOSTINO, Michael, J.; 26 Wolcott Avenue, Andover, MA 01810 (US). STEININGER, Robert, J., II; 100 Reed Street, Cambridge, MA 02140 (US). WONG, Gordon, G.; 239 Clark Road, Brookline, MA 02146 (US). CLARK, Hilary, F.; 146 Webster Avenue #2, Cambridge, MA 02141 (US). FECHTEL, Kim; 46 Marion Road, Arlington, MA 02174 (US).  <b>(74) Agent:</b> SPRUNGER, Suzanne, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM  <b>(57) Abstract</b>  Novel polynucleotides and the proteins encoded thereby are disclosed.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

5           This application is a continuation-in-part of provisional application Ser. No. 60/066,804, filed November 26, 1997, which is incorporated by reference herein.

FIELD OF THE INVENTION

10           The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

BACKGROUND OF THE INVENTION

15           Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

20

25

### SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265;
- 10 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bd306\_7 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bd306\_7 deposited under accession number ATCC 98599;
- 15 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bd306\_7 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone bd306\_7 deposited under accession number ATCC 98599;
- 20 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;
- 25 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and
- (l) a polynucleotide that hybridizes under stringent conditions to any  
30 one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265; the nucleotide sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265; the nucleotide sequence of the full-length protein coding sequence of clone bd306\_7 deposited under accession number ATCC 98599; or the

nucleotide sequence of a mature protein coding sequence of clone bd306\_7 deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone bd306\_7 deposited under accession number ATCC 98599. In yet other preferred  
5 embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2 from amino acid 148 to amino acid 189. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably  
10 twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 195 to amino acid 204 of SEQ ID NO:2.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ  
15 ID NO:1.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
    - (i) preparing one or more polynucleotide probes that hybridize  
20 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
      - (aa) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and
      - (ab) the nucleotide sequence of the cDNA insert of clone  
25 bd306\_7 deposited under accession number ATCC 98599; and
    - (ii) hybridizing said probe(s) to human DNA; and
    - (iii) isolating the DNA polynucleotide detected with the probe(s);
- and
- (b) a process comprising the steps of:
    - (i) preparing one or more polynucleotide primers that  
30 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and

(bb) the nucleotide sequence of the cDNA insert of clone bd306\_7 deposited under accession number ATCC 98599; and

5 (ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending  
10 contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265, and extending  
15 contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID  
20 NO:1 from nucleotide 132 to nucleotide 1265, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265.

In other embodiments, the present invention provides a composition comprising  
25 a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:2;

(b) the amino acid sequence of SEQ ID NO:2 from amino acid 148 to amino acid 189;

30 (c) fragments of the amino acid sequence of SEQ ID NO:2 comprising eight consecutive amino acids of SEQ ID NO:2; and

(d) the amino acid sequence encoded by the cDNA insert of clone bd306\_7 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:2 from amino acid 148 to amino acid 189. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 195 to amino acid 204 of SEQ ID NO:2.

10 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID  
15 NO:3 from nucleotide 719 to nucleotide 1855;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 779 to nucleotide 1855;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fj283\_11 deposited under accession  
20 number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fj283\_11 deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fj283\_11 deposited under accession number  
25 ATCC 98599;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fj283\_11 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 719 to nucleotide 1855; the nucleotide sequence of SEQ ID NO:3 from nucleotide 779 to nucleotide 1855; the nucleotide sequence of the full-length protein coding sequence of clone fj283\_11 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone fj283\_11 deposited  
10 under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fj283\_11 deposited under accession number ATCC 98599. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 27.  
15 In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of  
20 SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 184 to amino acid 193 of SEQ ID NO:4.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3.

Further embodiments of the invention provide isolated polynucleotides produced  
25 according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

30 (aa) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and

(ab) the nucleotide sequence of the cDNA insert of clone fj283\_11 deposited under accession number ATCC 98599; and

(ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

5 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and

10 (bb) the nucleotide sequence of the cDNA insert of clone fj283\_11 deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii).

15 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3. Also preferably the polynucleotide isolated  
20 according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 719 to nucleotide 1855, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 719 to nucleotide 1855, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 719 to  
25 nucleotide 1855. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 779 to nucleotide 1855, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 779 to nucleotide 1855, to a nucleotide sequence corresponding to the 3' end  
30 of said sequence of SEQ ID NO:3 from nucleotide 779 to nucleotide 1855.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:4;

(b) the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 27;

(c) fragments of the amino acid sequence of SEQ ID NO:4 comprising eight consecutive amino acids of SEQ ID NO:4;

5 (d) the amino acid sequence encoded by the cDNA insert of clone fj283\_11 deposited under accession number ATCC 98599; and

(e) the amino acid sequence encoded by the cDNA insert of clone fj283\_6 deposited under accession number ATCC xxxxx;

the protein being substantially free from other mammalian proteins. Preferably such  
10 protein comprises the amino acid sequence of SEQ ID NO:4 or the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 27. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID  
15 NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 184 to amino acid 193 of SEQ ID NO:4.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

20 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 982 to nucleotide 2118;

25 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 1042 to nucleotide 2118;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 621 to nucleotide 1248;

30 (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fj283\_6 deposited under accession number ATCC xxxxx;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fj283\_6 deposited under accession number ATCC xxxxx;

- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fj283\_6 deposited under accession number ATCC xxxxx;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fj283\_6 deposited under accession number ATCC xxxxx;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:32 from nucleotide 982 to nucleotide 2118; the nucleotide sequence of SEQ ID NO:32 from nucleotide 1042 to nucleotide 2118; the nucleotide sequence of SEQ ID NO:32 from nucleotide 621 to nucleotide 1248; the nucleotide sequence of the full-length protein coding sequence of clone fj283\_6 deposited under accession number ATCC xxxxx; or the nucleotide sequence of a mature protein coding sequence of clone fj283\_6 deposited under accession number ATCC xxxxx. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fj283\_6 deposited under accession number ATCC xxxxx. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 184 to amino acid 193 of SEQ ID NO:4.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:32.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

5 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:32, but excluding the poly(A) tail at the 3' end of SEQ ID NO:32; and

10 (ab) the nucleotide sequence of the cDNA insert of clone fj283\_6 deposited under accession number ATCC xxxxx; and

(ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the probe(s);

and

15 (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

20 (ba) SEQ ID NO:32, but excluding the poly(A) tail at the 3' end of SEQ ID NO:32; and

(bb) the nucleotide sequence of the cDNA insert of clone fj283\_6 deposited under accession number ATCC xxxxx; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

25 (iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:32, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:32 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:32, but  
30 excluding the poly(A) tail at the 3' end of SEQ ID NO:32. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:32 from nucleotide 982 to nucleotide 2118, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:32 from nucleotide 982 to nucleotide 2118, to a nucleotide

sequence corresponding to the 3' end of said sequence of SEQ ID NO:32 from nucleotide 982 to nucleotide 2118. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:32 from nucleotide 1042 to nucleotide 2118, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:32 from nucleotide 1042 to nucleotide 2118, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:32 from nucleotide 1042 to nucleotide 2118. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:32 from nucleotide 621 to nucleotide 1248, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:32 from nucleotide 621 to nucleotide 1248, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:32 from nucleotide 621 to nucleotide 1248.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fk317\_3 deposited under accession number ATCC 98599;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fk317\_3 deposited under accession number ATCC 98599;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone fk317\_3 deposited under accession number ATCC 98599;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone fk317\_3 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:6;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and

5 (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624; the nucleotide sequence of the full-length protein coding sequence of clone fk317\_3 deposited under accession number ATCC 98599; 10 or the nucleotide sequence of a mature protein coding sequence of clone fk317\_3 deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone fk317\_3 deposited under accession number ATCC 98599. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein 15 comprising the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 72. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:6, or a 20 polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:6.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.

25 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group 30 consisting of:

(aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(ab) the nucleotide sequence of the cDNA insert of clone fk317\_3 deposited under accession number ATCC 98599; and

- (ii) hybridizing said probe(s) to human DNA; and
- (iii) isolating the DNA polynucleotide detected with the probe(s);

and

- 5 (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:5, but excluding the poly(A) tail at the
    - 10 3' end of SEQ ID NO:5; and
    - (bb) the nucleotide sequence of the cDNA insert of clone fk317\_3 deposited under accession number ATCC 98599; and
  - (ii) hybridizing said primer(s) to human DNA;
  - (iii) amplifying human DNA sequences; and
  - 15 (iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:5, but excluding the

20 poly(A) tail at the 3' end of SEQ ID NO:5. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624, to a nucleotide sequence

25 corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 30 (a) the amino acid sequence of SEQ ID NO:6;
- (b) the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 72;
- (c) fragments of the amino acid sequence of SEQ ID NO:6 comprising eight consecutive amino acids of SEQ ID NO:6; and

(d) the amino acid sequence encoded by the cDNA insert of clone fk317\_3 deposited under accession number ATCC 98599; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6 or the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 72. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 56 to amino acid 65 of SEQ ID NO:6.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone k213\_2x deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone k213\_2x deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone k213\_2x deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone k213\_2x deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:8;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

5 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578; the nucleotide sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578; the nucleotide sequence of the full-length protein coding  
10 sequence of clone k213\_2x deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone k213\_2x deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone k213\_2x deposited under accession number ATCC 98599. In further preferred  
15 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having  
20 biological activity, the fragment comprising the amino acid sequence from amino acid 32 to amino acid 41 of SEQ ID NO:8.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7.

Further embodiments of the invention provide isolated polynucleotides produced  
25 according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

30 (aa) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and

(ab) the nucleotide sequence of the cDNA insert of clone k213\_2x deposited under accession number ATCC 98599; and

(ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

5 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and

10 (bb) the nucleotide sequence of the cDNA insert of clone k213\_2x deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii).

15 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7. Also preferably the polynucleotide isolated  
20 according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 357 to  
25 nucleotide 578. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578, to a nucleotide sequence corresponding to the 3' end of  
30 said sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:8;

(b) fragments of the amino acid sequence of SEQ ID NO:8 comprising eight consecutive amino acids of SEQ ID NO:8; and

(c) the amino acid sequence encoded by the cDNA insert of clone k213\_2x deposited under accession number ATCC 98599;

5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino  
10 acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 32 to amino acid 41 of SEQ ID NO:8.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598;

20 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone na316\_1 deposited under accession number ATCC 98599;

25 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone na316\_1 deposited under accession number ATCC 98599;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone na316\_1 deposited under accession number ATCC 98599;

30 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone na316\_1 deposited under accession number ATCC 98599;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:10;

5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

10 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598; the nucleotide sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598; the nucleotide sequence of the full-length protein coding sequence of clone na316\_1 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone na316\_1 deposited  
15 under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone na316\_1 deposited under accession number ATCC 98599. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological  
20 activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:10.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:  
30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and

- (ab) the nucleotide sequence of the cDNA insert of clone na316\_1 deposited under accession number ATCC 98599; and
- (ii) hybridizing said probe(s) to human DNA; and
- (iii) isolating the DNA polynucleotide detected with the probe(s);

and

- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and
- (bb) the nucleotide sequence of the cDNA insert of clone na316\_1 deposited under accession number ATCC 98599; and
- (ii) hybridizing said primer(s) to human DNA;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- 5 (b) fragments of the amino acid sequence of SEQ ID NO:10 comprising eight consecutive amino acids of SEQ ID NO:10; and
- (c) the amino acid sequence encoded by the cDNA insert of clone na316\_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins. Preferably such  
10 protein comprises the amino acid sequence of SEQ ID NO:10. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:10, or a protein comprising a fragment of the amino acid sequence of  
15 SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:10.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID  
20 NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986;
- 25 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone nf93\_20 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone nf93\_20 deposited under accession number ATCC 98599;
- 30 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone nf93\_20 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone nf93\_20 deposited under accession number ATCC 98599;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:12;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986; the nucleotide sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986; the nucleotide sequence of the full-length protein coding sequence of clone nf93\_20 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone nf93\_20 deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone nf93\_20 deposited under accession number ATCC 98599. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 100 to amino acid 109 of SEQ ID NO:12.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and

(ab) the nucleotide sequence of the cDNA insert of clone nf93\_20 deposited under accession number ATCC 98599; and

5 (ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

10 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and

15 (bb) the nucleotide sequence of the cDNA insert of clone nf93\_20 deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii).

20 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11. Also preferably the  
25 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide  
30 354 to nucleotide 986. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from

nucleotide 408 to nucleotide 986, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group  
5 consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
  - (b) fragments of the amino acid sequence of SEQ ID NO:12 comprising eight consecutive amino acids of SEQ ID NO:12; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone  
10 nf93\_20 deposited under accession number ATCC 98599;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably  
15 comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:12, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 100 to amino acid 109 of SEQ ID NO:12.

In one embodiment, the present invention provides a composition comprising an  
20 isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID  
25 NO:13 from nucleotide 1381 to nucleotide 1821;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone np164\_1 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the  
30 cDNA insert of clone np164\_1 deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone np164\_1 deposited under accession number ATCC 98599;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone np164\_1 deposited under accession number ATCC 98599;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;

5 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:14;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

10 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID  
15 NO:13 from nucleotide 301 to nucleotide 1821; the nucleotide sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821; the nucleotide sequence of the full-length protein coding sequence of clone np164\_1 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone np164\_1 deposited under accession number ATCC 98599. In other preferred embodiments, the  
20 polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone np164\_1 deposited under accession number ATCC 98599. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most  
25 preferably thirty) consecutive amino acids of SEQ ID NO:14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 248 to amino acid 257 of SEQ ID NO:14.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ  
30 ID NO:13.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (aa) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and

(ab) the nucleotide sequence of the cDNA insert of clone np164\_1 deposited under accession number ATCC 98599; and

(ii) hybridizing said probe(s) to human DNA; and

10 (iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

15 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and

(bb) the nucleotide sequence of the cDNA insert of clone np164\_1 deposited under accession number ATCC 98599; and

20 (ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and  
25 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide  
30 1821, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID

NO:13 from nucleotide 1381 to nucleotide 1821, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821.

5 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;
- (b) fragments of the amino acid sequence of SEQ ID NO:14 comprising  
10 eight consecutive amino acids of SEQ ID NO:14; and
- (c) the amino acid sequence encoded by the cDNA insert of clone np164\_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:14. In further preferred  
15 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:14, or a protein comprising a fragment of the amino acid sequence of  
20 SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 248 to amino acid 257 of SEQ ID NO:14.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;
- 25 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pe204\_1 deposited under accession number ATCC 98599;
- 30 (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pe204\_1 deposited under accession number ATCC 98599;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pe204\_1 deposited under accession number ATCC 98599;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pe204\_1 deposited under accession number ATCC 98599;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;

5 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:16;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

10 (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ; and

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID  
15 NO:15 from nucleotide 148 to nucleotide 537; the nucleotide sequence of the full-length protein coding sequence of clone pe204\_1 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone pe204\_1 deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert  
20 of clone pe204\_1 deposited under accession number ATCC 98599. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:16, or a polynucleotide encoding  
25 a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 60 to amino acid 69 of SEQ ID NO:16.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.

30 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (aa) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and

(ab) the nucleotide sequence of the cDNA insert of clone pe204\_1 deposited under accession number ATCC 98599; and

(ii) hybridizing said probe(s) to human DNA; and

10 (iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

15 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and

(bb) the nucleotide sequence of the cDNA insert of clone pe204\_1 deposited under accession number ATCC 98599; and

20 (ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15, and  
25 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide  
30 537, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:16;
- 5 (b) fragments of the amino acid sequence of SEQ ID NO:16 comprising eight consecutive amino acids of SEQ ID NO:16; and
- (c) the amino acid sequence encoded by the cDNA insert of clone pe204\_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins. Preferably such  
10 protein comprises the amino acid sequence of SEQ ID NO:16. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino  
15 acids of SEQ ID NO:16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 60 to amino acid 69 of SEQ ID NO:16.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 20 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109;
- 25 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ya1\_1 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ya1\_1 deposited under accession number ATCC 98599;
- 30 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ya1\_1 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ya1\_1 deposited under accession number ATCC 98599;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:18;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109; the nucleotide sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109; the nucleotide sequence of the full-length protein coding sequence of clone ya1\_1 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone ya1\_1 deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ya1\_1 deposited under accession number ATCC 98599. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 176 to amino acid 185 of SEQ ID NO:18.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:17.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and

(ab) the nucleotide sequence of the cDNA insert of clone ya1\_1 deposited under accession number ATCC 98599; and

5 (ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

10 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and

15 (bb) the nucleotide sequence of the cDNA insert of clone ya1\_1 deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii).

20 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:17 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17. Also preferably the  
25 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide  
30 24 to nucleotide 1109. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from

nucleotide 1050 to nucleotide 1109, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group  
5 consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
  - (b) fragments of the amino acid sequence of SEQ ID NO:18 comprising eight consecutive amino acids of SEQ ID NO:18; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone  
10 ya1\_1 deposited under accession number ATCC 98599;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:18. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably  
15 comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:18, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 176 to amino acid 185 of SEQ ID NO:18.

In one embodiment, the present invention provides a composition comprising an  
20 isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID  
25 NO:19 from nucleotide 270 to nucleotide 734;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604;
- (e) a polynucleotide comprising the nucleotide sequence of the full-  
30 length protein coding sequence of clone yb8\_1 deposited under accession number ATCC 98599;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yb8\_1 deposited under accession number ATCC 98599;

- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yb8\_1 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yb8\_1 deposited under accession number ATCC 98599;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:20;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734; the nucleotide sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734; the nucleotide sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604; the nucleotide sequence of the full-length protein coding sequence of clone yb8\_1 deposited under accession number ATCC 98599; or the nucleotide sequence of a mature protein coding sequence of clone yb8\_1 deposited under accession number ATCC 98599. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yb8\_1 deposited under accession number ATCC 98599. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20 from amino acid 70 to amino acid 236. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 113 to amino acid 122 of SEQ ID NO:20.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:19.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 5 (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - 10 (aa) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and
    - (ab) the nucleotide sequence of the cDNA insert of clone yb8\_1 deposited under accession number ATCC 98599; and
  - (ii) hybridizing said probe(s) to human DNA; and
  - (iii) isolating the DNA polynucleotide detected with the
- 15 probe(s);
- and
- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
  - 20 the group consisting of:
    - (ba) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and
    - (bb) the nucleotide sequence of the cDNA insert of clone yb8\_1 deposited under accession number ATCC 98599; and
  - 25 (ii) hybridizing said primer(s) to human DNA;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide product of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19, and  
30 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide

734, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734. Also preferably the polynucleotide isolated according to the above  
5 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734. Also preferably  
10 the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from  
15 nucleotide 85 to nucleotide 1604.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:20;
- 20 (b) the amino acid sequence of SEQ ID NO:20 from amino acid 70 to amino acid 236;
- (c) fragments of the amino acid sequence of SEQ ID NO:20 comprising eight consecutive amino acids of SEQ ID NO:20; and
- (d) the amino acid sequence encoded by the cDNA insert of clone  
25 yb8\_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:20 or the amino acid sequence of SEQ ID NO:20 from amino acid 70 to amino acid 236. In further preferred  
30 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:20, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 113 to amino acid 122 of SEQ ID NO:20.

In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or  
5 modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.

Processes are also provided for producing a protein, which comprise:

- (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and
- 10 (b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention.

Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which  
15 specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

20

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

25

#### DETAILED DESCRIPTION

##### ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone  
30 in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have

determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

10        Clone "bd306\_7"

A polynucleotide of the present invention has been identified as clone "bd306\_7". bd306\_7 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bd306\_7 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "bd306\_7 protein").

The nucleotide sequence of bd306\_7 as presently determined is reported in SEQ ID NO:1, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the bd306\_7 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2. Amino acids 11 to 23 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the bd306\_7 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone bd306\_7 should be approximately 3700 bp.

The nucleotide sequence disclosed herein for bd306\_7 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bd306\_7 demonstrated at least some similarity with sequences identified as AA027096 (zk04d03.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 469541 3'), AA027135 (zk04d03.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 469541 5'), AA166312 (ms42g11.r1 Life Tech mouse embryo 13 5dpc 10666014 Mus musculus cDNA clone 614276 5' similar to TR E238793 E238793 DUALIN), AA535890

(nf94a03.s1 NCI\_CGAP\_Co3 Homo sapiens cDNA clone IMAGE:927532), H14467 (yl25g07.r1 Homo sapiens cDNA clone 159324 5' similar to contains HGR repetitive element), T21281 (Human gene signature HUMGS02637), T61016 (Total DNA sequence from cosmid clones LP(2)127 and LP(2)128), U47621 (Human nucleolar autoantigen No55 mRNA, complete cds), W51808 (zc48g04.r1 Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 325590 5' similar to PIR:S20742 S20742 synaptonemal complex protein Sc65 - rat; contains Alu repetitive element; mRNA sequence), and X97607 (G.gallus mRNA for cartilage associated protein). The predicted amino acid sequence disclosed herein for bd306\_7 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted bd306\_7 protein demonstrated at least some similarity to sequences identified as R95913 (Neural thread protein [Homo sapiens]), U47621 (nucleolar autoantigen No55 [Homo sapiens]), and X97607 (cartilage associated protein [Gallus gallus]). Two regions of bd306\_7 protein (amino acids 148-217 and 298-367 of SEQ ID NO:2) align with the same region, amino acids 145-214, of cartilage associated protein. The homology between bd306\_7 protein and nucleolar autoantigen No55 is also good, but in this case it appears that bd306\_7 amino acids 148-189 is similar to two regions of No55 (amino acids 145-186 and 296-337), and bd306\_7 amino acids 298-367 are also similar to nearly the same two regions of No55 (amino acids 145-214 and 296-365). This implies that two regions in bd306\_7 (roughly 148-189 and 298-367) are similar to each other, and one copy of this region is found in cartilage associated protein, but both are present in No55. Cartilage associated protein is reported to be localized to the extracellular matrix {J. Cell Sci 1997 110( Pt 12):1351-1359}, while No55 is found in the granular component of the nucleolus {Mol Biol Cell 1996 7(7):1015-1024}. Based upon sequence similarity, bd306\_7 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of bd306\_7 also indicates that it may contain an Alu repetitive element.

#### Clone "fj283\_11" and Clone "fj283\_6"

Polynucleotides of the present invention have been identified as clone "fj283\_11" and clone "fj283\_6". fj283\_11 and fj283\_6 were isolated from a human adult lung carcinoma cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or were identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of

the encoded protein. fj283\_11 and fj283\_6 are full-length clones, including the entire coding sequence of a secreted protein (also referred to herein as "fj283 protein").

The nucleotide sequence of fj283\_11 as presently determined is reported in SEQ ID NO:3, and includes a poly(A) tail. The nucleotide sequence of fj283\_6 as presently  
 5 determined is reported in SEQ ID NO:32, and includes a poly(A) tail. Although cDNA clones fj283\_11 and fj283\_6 have different nucleotide sequences, perhaps as a result of alternative splicing of a common primary mRNA transcript (particularly between nucleotide 402 and nucleotide 618 of SEQ ID NO:32), these clones are predicted to encode the same protein. What applicants presently believe to be the proper reading frame and  
 10 the predicted amino acid sequence of the fj283 protein corresponding to the foregoing nucleotide sequences is reported in SEQ ID NO:4. Amino acids 8 to 20 of SEQ ID NO:4 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal  
 15 sequence not be separated from the remainder of the fj283 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone fj283\_11 should be approximately 3350 bp. The EcoRI/NotI restriction fragment obtainable from the deposit containing clone fj283\_6 should be approximately 2700 bp.

The nucleotide sequences disclosed herein for fj283\_11 and fj283\_6 were searched  
 20 against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. fj283\_11 and/or fj283\_6 demonstrated at least some similarity with sequences identified as AA052962 (zl70c02.s1 Stratagene colon (#937204) Homo sapiens cDNA clone 509954 3' similar to gb D14531 60S RIBOSOMAL PROTEIN L9 (HUMAN)), AA080949 (zn04d12.r1 Stratagene hNT),  
 25 AA160948 (zq40e12.r1 Stratagene hNT neuron (#937233) Homo sapiens cDNA clone 632206 5'), AA195089 (zr34c02.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 665282 5', mRNA sequence), AA258887 (zs32b02.r1 NCI\_CGAP\_GCB1 Homo sapiens cDNA clone IMAGE:686859 5'), H97993 (yw06e03.s1 Homo sapiens cDNA clone 251452 3'), R19768 (yg40g06.r1 Homo sapiens cDNA clone 34951 5'), U09953 (Human ribosomal  
 30 protein L9 mRNA, complete cds), Z73639 (Human DNA sequence from cosmid V389H8 on chromosome X; Contains mRNA near btk gene involved in a-gamma-globulinemia, ESTs, STS), and Z73901 (Human DNA sequence from cosmid V389H8, between markers DXS366 and DXS87 on chromosome X contains pseudogene, mRNA near btk gene involved in a-gamma-globulinemia, ESTs, STSs). The predicted amino acid sequence

disclosed herein for the fj283 protein was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted fj283 protein demonstrated at least some similarity to sequences identified as AB011084 (KIAA0512 protein [Homo sapiens]) and U09953 (ribosomal protein L9 [Homo sapiens]).

5 Based upon sequence similarity, fj283 proteins and each similar protein or peptide may share at least some activity. Profile hidden markov model analysis has revealed the presence of an Armadillo/beta-catenin-like domain within the predicted fj283 protein sequence. The armadillo multigene family comprises many proteins widely differing in sizes and functions which have in common a variable number of tandemly repeated arm

10 sequences of about 42 amino acids in length. Many, but not all, armadillo-repeat-containing proteins are nuclear in localization. The predicted fj283 protein does not appear to be of the nuclear variety, but rather appears to be an extracellular protein.

#### Clone "fk317\_3"

15 A polynucleotide of the present invention has been identified as clone "fk317\_3". fk317\_3 was isolated from a human adult kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. fk317\_3 is a full-length clone,

20 including the entire coding sequence of a secreted protein (also referred to herein as "fk317\_3 protein").

The nucleotide sequence of fk317\_3 as presently determined is reported in SEQ ID NO:5, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the fk317\_3 protein

25 corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone fk317\_3 should be approximately 1400 bp.

The nucleotide sequence disclosed herein for fk317\_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and

30 FASTA search protocols. fk317\_3 demonstrated at least some similarity with sequences identified as AA568588 (nm21b11.s1 NCI\_CGAP\_Co10 Homo sapiens cDNA clone IMAGE:1060797), AC002326 (Genomic sequence from Human 6, complete sequence), H48562 (yq78g07.s1 Homo sapiens cDNA clone 201948 3' similar to contains Alu repetitive element; contains MER30 repetitive element), T67164 (Human alpha-N-

acetylglucosaminidase gene), and Z46941 (H.sapiens DNA for alu repeats). The predicted amino acid sequence disclosed herein for fk317\_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted fk317\_3 protein demonstrated at least some similarity to sequences identified  
5 as X55777 (put. ORF [Homo sapiens]). Based upon sequence similarity, fk317\_3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the fk317\_3 protein sequence centered around amino acid 42 of SEQ ID NO:6. The nucleotide sequence of fk317\_3 indicates that it may contain an Alu repetitive element.

10

Clone "k213\_2x"

A polynucleotide of the present invention has been identified as clone "k213\_2x". Secreted cDNA clones were first isolated from a murine adult bone marrow (stromal cell line FCM-4) cDNA library using methods which are selective for cDNAs encoding  
15 secreted proteins (see U.S. Pat. No. 5,536,637), or were identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. These murine cDNAs were then used to isolate k213\_2x, a full-length human cDNA clone, including the entire coding sequence of a secreted protein (also referred to herein as "k213\_2x protein").

20 The nucleotide sequence of k213\_2x as presently determined is reported in SEQ ID NO:7, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the k213\_2x protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:8. Amino acids 26 to 38 are a predicted leader/signal sequence, with the predicted mature amino  
25 acid sequence beginning at amino acid 39. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the k213\_2x protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone k213\_2x should be approximately 1900 bp.

30 The nucleotide sequence disclosed herein for k213\_2x was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. k213\_2x demonstrated at least some similarity with sequences identified as AA123852 (mp96e08.r1 Soares 2NbMT Mus musculus cDNA clone 577094 5'), AA362005 (EST71348 T-cell lymphoma Homo sapiens cDNA 5' end), AA436477

(zv08f05.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 753057 3'), AA436528 (zv08f05.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 753057 5'), AA643506 (nq86f04.s1 NCI\_CGAP\_Co9 Homo sapiens cDNA clone IMAGE:1159231, mRNA sequence), F13485 (H. sapiens partial cDNA sequence; clone c-3dh08), and T19502  
5 (Human gene signature HUMGS00560). Based upon sequence similarity, k213\_2x proteins and each similar protein or peptide may share at least some activity.

#### Clone "na316\_1"

A polynucleotide of the present invention has been identified as clone "na316\_1".  
10 na316\_1 was isolated from a human adult brain (corpus callosum) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. na316\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to  
15 herein as "na316\_1 protein").

The nucleotide sequence of na316\_1 as presently determined is reported in SEQ ID NO:9, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the na316\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10. Amino  
20 acids 30 to 42 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 43. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the na316\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone  
25 na316\_1 should be approximately 900 bp.

The nucleotide sequence disclosed herein for na316\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database. The TopPredII computer program predicts two potential transmembrane domains within the na316\_1 protein  
30 sequence, centered around amino acids 31 and 66 of SEQ ID NO:10, respectively.

#### Clone "nf93\_20"

A polynucleotide of the present invention has been identified as clone "nf93\_20". nf93\_20 was isolated from a human adult brain (substantia nigra) cDNA library using

methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. nf93\_20 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to  
5 herein as "nf93\_20 protein").

The nucleotide sequence of nf93\_20 as presently determined is reported in SEQ ID NO:11, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the nf93\_20 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12. Amino  
10 acids 6 to 18 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the nf93\_20 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone  
15 nf93\_20 should be approximately 2000 bp.

The nucleotide sequence disclosed herein for nf93\_20 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. nf93\_20 demonstrated at least some similarity with sequences identified as AA063620 (ze87g07.s1 Soares fetal heart NbHH19W Homo sapiens cDNA  
20 clone 366012 3'), AA317410 (EST19337 Retina II Homo sapiens cDNA 5' end), H29417 (ym60e07.r1 Homo sapiens cDNA clone 52631 5'), and N41425 (yw93e08.r1 Homo sapiens cDNA clone 259814 5'). Based upon sequence similarity, nf93\_20 proteins and each similar protein or peptide may share at least some activity.

25       Clone "np164\_1"

A polynucleotide of the present invention has been identified as clone "np164\_1". np164\_1 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis  
30 of computer analysis of the amino acid sequence of the encoded protein. np164\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "np164\_1 protein").

The nucleotide sequence of np164\_1 as presently determined is reported in SEQ ID NO:13, and includes a poly(A) tail. What applicants presently believe to be the proper

reading frame and the predicted amino acid sequence of the np164\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:14. Amino acids 348 to 360 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 361. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the np164\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone np164\_1 should be approximately 2100 bp.

The nucleotide sequence disclosed herein for np164\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. np164\_1 demonstrated at least some similarity with sequences identified as N63143 (yz37c12.s1 Homo sapiens cDNA clone 285238 3'), T19992 (Human gene signature HUMGS01129), Z46676 (Caenorhabditis elegans cosmid C08B11, complete sequence), and Z74910 (S.cerevisiae chromosome XV reading frame ORF YOR002w). The predicted amino acid sequence disclosed herein for np164\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted np164\_1 protein demonstrated at least some similarity to sequences identified as Z46676 (C08B11.8 [Caenorhabditis elegans]) and Z74910 (ORF YOR002w [Saccharomyces cerevisiae]). Based upon sequence similarity, np164\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts ten potential transmembrane domains within the np164\_1 protein sequence, centered around amino acids 4, 114, 165, 229, 293, 322, 360, 386, 436, and 465 of SEQ ID NO:14, respectively.

#### Clone "pe204\_1"

A polynucleotide of the present invention has been identified as clone "pe204\_1". pe204\_1 was isolated from a human adult blood (chronic myelogenous leukemia K5) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pe204\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pe204\_1 protein").

The nucleotide sequence of pe204\_1 as presently determined is reported in SEQ ID NO:15, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pe204\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:16. Amino acids 116 to 128 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 129. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pe204\_1 protein.

10 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pe204\_1 should be approximately 1100 bp.

The nucleotide sequence disclosed herein for pe204\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pe204\_1 demonstrated at least some similarity with sequences identified as AA279961 (zs92h08.s1 NCI\_CGAP\_GCB1 Homo sapiens cDNA clone 704991 3'), AA306911 (EST178043 Colon carcinoma (HCC) cell line Homo sapiens cDNA 5' end), AC002086 (Human PAC clone DJ525N14), AC002094 (Genomic sequence from Human 17, complete sequence), T97749 (ye58c04.s1 Homo sapiens cDNA clone), Z74696 (Human DNA sequence from cosmid 203C2, between markers DXS6791 and DXS8038 on chromosome X contains ESTs), Z80901 (Human DNA sequence from cosmid N119A7 on chromosome 22q12-qter), and Z82245 (Human DNA sequence \*\*\* SEQUENCING IN PROGRESS \*\*\* from clone 799F10; HTGS phase 1). The predicted amino acid sequence disclosed herein for pe204\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pe204\_1 protein demonstrated at least some similarity to sequences identified as K02113 (Gallus gallus vitellogenin [Gallus gallus]). Based upon sequence similarity, pe204\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the pe204\_1 protein sequence, one centered around amino acid 50 and another around amino acid 90 of SEQ ID NO:16.

#### Clone "ya1\_1"

A polynucleotide of the present invention has been identified as clone "ya1\_1". ya1\_1 was isolated from a human adult testes cDNA library and was identified as

encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ya1\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ya1\_1 protein").

The nucleotide sequence of ya1\_1 as presently determined is reported in SEQ ID NO:17, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ya1\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:18. Amino acids 330 to 342 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 343. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ya1\_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ya1\_1 should be approximately 1400 bp.

The nucleotide sequence disclosed herein for ya1\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ya1\_1 demonstrated at least some similarity with sequences identified as AA431507 (zw76e05.r1 Soares testis NHT Homo sapiens cDNA clone 782144 5') and F03332 (H. sapiens partial cDNA sequence; clone c-1tg07). Based upon sequence similarity, ya1\_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the ya1\_1 protein sequence centered around amino acid 156 and around amino acid 332 of SEQ ID NO:18, respectively. The nucleotide sequence of ya1\_1 indicates that it may contain an Alu repetitive element.

#### Clone "yb8\_1"

A polynucleotide of the present invention has been identified as clone "yb8\_1". yb8\_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yb8\_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "yb8\_1 protein").

The nucleotide sequence of yb8\_1 as presently determined is reported in SEQ ID NO:19, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yb8\_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:20. Amino acids 69 to 81

are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 82. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yb8\_1 protein.

- 5           The EcoRI/NotI restriction fragment obtainable from the deposit containing clone yb8\_1 should be approximately 1800 bp.

          The nucleotide sequence disclosed herein for yb8\_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yb8\_1 demonstrated at least some similarity with sequences  
10 identified as AA418057 (zv97a06.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 767698 5' similar to TR:G1143719 G1143719 RS-REX-B), L10334 (Homo sapiens neuroendocrine-specific protein B (NSP) mRNA, complete cds), U17603 (Rattus norvegicus rS-Rex-s mRNA, complete cds), and W19986 (zb38e09.r1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 305896 5', mRNA sequence). The predicted  
15 amino acid sequence disclosed herein for yb8\_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted yb8\_1 protein demonstrated at least some similarity to sequences identified as L10334 (neuroendocrine-specific proteins B and C [Homo sapiens]) and U17603 (rS-Rex-s [Rattus norvegicus]). Based upon sequence similarity, yb8\_1 proteins and each similar  
20 protein or peptide may share at least some activity. The predicted yb8\_1 protein shows significant (60% identity) amino acid similarity to the neuro-endocrine specific protein (NSP) family of proteins. Roebroek *et al.* (1993, *J. Biol Chem.* 268: 13439, which is incorporated by reference herein) report observing three transcripts from this gene family: NSP-A (3.4 kb), -B (2.3 kb), and -C (1.8 kb); they encode proteins of 776, 356, and 208  
25 amino acids, respectively. Roebroek *et al.* also observe that these three transcripts are identical at the 3' end and only differ over a short portion near their 5' ends, and are thus possible splice variants. NSP-A and NSP-C were found in neural and endocrine tissues while NSP-B was found only in a lung carcinoma cell line (Roebrek *et al.* state that NSP-B is "aberrant" suggesting that it might be an artifact). The C-terminal portions of the protein  
30 sequences from all three transcripts are identical. The predicted yb8\_1 protein shows strong amino acid similarity within this region and is about as long as NSP-C. Thus the predicted yb8\_1 protein appears to be related to NSP-C. The TopPredII computer program predicts two potential transmembrane domains within the yb8\_1 protein sequence, centered around amino acids 82 and 174 of SEQ ID NO:20, respectively.

### Deposit of Clones

Clones bd306\_7, fj283\_11, fk317\_3, k213\_2x, na316\_1, nf93\_20, np164\_1, pe204\_1, ya1\_1, and yb8\_1 were deposited on November 26, 1997 with the American Type Culture  
5 Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98599, from which each clone comprising a particular polynucleotide is obtainable. Clone fj283\_6 was deposited on 17 November, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit  
10 under the Budapest Treaty and was given the accession number ATCC xxxxxx. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806.

Each clone has been transfected into separate bacterial cells (*E. coli*) in the  
15 accession number ATCC 98599 composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1A and 1B, respectively. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion  
20 of a new polylinker to facilitate cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In  
25 such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite  
30 deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an

oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

	<u>Clone</u>	<u>Probe Sequence</u>
5	bd306_7	SEQ ID NO:21
	fj283_11	SEQ ID NO:22
	fj283_6	SEQ ID NO:31
	fk317_3	SEQ ID NO:23
	k213_2x	SEQ ID NO:24
10	na316_1	SEQ ID NO:25
	nf93_20	SEQ ID NO:26
	np164_1	SEQ ID NO:27
	pe204_1	SEQ ID NO:28
	ya1_1	SEQ ID NO:29
15	yb8_1	SEQ ID NO:30

In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

The design of the oligonucleotide probe should preferably follow these parameters:

- (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
- (b) It should be designed to have a  $T_m$  of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).

The oligonucleotide should preferably be labeled with  $\gamma$ -<sup>32</sup>P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100  $\mu$ l of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100  $\mu$ g/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in  
5 fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100  $\mu$ g/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

10 Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100  $\mu$ g/ml of yeast RNA, and 10 mM EDTA (approximately  
15 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to  $1e+6$  dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes.  
20 A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated  
25 using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example,  
30 as described in H.U. Saragovi, *et al.*, Bio/Technology 10, 773-778 (1992) and in R.S. McDowell, *et al.*, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to

the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

5       The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or  
10 other host cell. The sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form.

      The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are  
15 derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed  
20 herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.

25       The chromosomal location corresponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately labeled polynucleotides of the present invention to chromosomes *in situ*. It may also be possible to determine the corresponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public  
30 databases, such as expressed sequence tags (ESTs), that have already been mapped to particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number. Searches using the GenBank accession numbers of these public database sequences can

then be performed at an Internet site provided by the National Center for Biotechnology Information having the address <http://www.ncbi.nlm.nih.gov/UniGene/>, in order to identify "UniGene clusters" of overlapping sequences. Many of the "UniGene clusters" so identified will already have been mapped to particular chromosomal sites.

- 5           Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, *Trends Pharmacol. Sci.* **15**(7): 250-254; Lavarosky *et al.*, 1997, *Biochem. Mol. Med.* **62**(1): 11-22; and Hampel, 1998, *Prog. Nucleic Acid Res. Mol. Biol.* **58**: 1-39; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided.
- 10           Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated,
- 20           through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, *Bioessays* **14**(9): 629-633; Zwaal *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* **90**(16): 7431-7435; Clark *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* **91**(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination,
- 25           preferably detected by positive/negative genetic selection strategies (Mansour *et al.*, 1988, *Nature* **336**: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably
- 30           are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms, part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information. For example, the TopPredII computer program can be used to predict the location of transmembrane domains in an amino acid sequence, domains which are described by the location of the center of the transmembrane domain, with at least ten transmembrane amino acids on each side of the reported central residue(s).

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics, Doolittle *ed.*, *Methods in Enzymology* **266**: 460-480; Altschul *et al.*, 1990, Basic local alignment search tool, *Journal of Molecular Biology* **215**: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, *Nature Genetics* **3**: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, *Proc. Natl. Acad. Sci. USA* **90**: 5873-5877; all of which are incorporated by reference herein). WU-BLAST version 2.0 executable programs for several UNIX platforms can be downloaded from <ftp://blast.wustl.edu/blast/executables>. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is

provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any form or manner without the express written consent of the author; but the posted executables may otherwise be freely used for commercial, nonprofit, or academic purposes. In all search programs in the suite

5 -- BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX -- the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any

10 integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one

15 through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps. The default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized.

Species homologues of the disclosed polynucleotides and proteins are also

20 provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with

25 the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species

30 homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian

species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, *Pan troglodytes*, *Gorilla gorilla*, *Pongo pygmaeus*, *Hylobates concolor*, *Macaca mulatta*, *Papio papio*, *Papio hamadryas*, *Cercopithecus aethiops*, *Cebus capucinus*, *Aotus trivirgatus*, *Sanguinus oedipus*, *Microcebus murinus*, *Mus musculus*, *Rattus norvegicus*,  
5 *Cricetulus griseus*, *Felis catus*, *Mustela vison*, *Canis familiaris*, *Oryctolagus cuniculus*, *Bos taurus*, *Ovis aries*, *Sus scrofa*, and *Equus caballus*, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuáñez, 1988, *Ann. Rev. Genet.* **22**: 323-351; O'Brien *et al.*, 1993, *Nature*  
10 *Genetics* **3**:103-112; Johansson *et al.*, 1995, *Genomics* **25**: 682-690; Lyons *et al.*, 1997, *Nature Genetics* **15**: 47-56; O'Brien *et al.*, 1997, *Trends in Genetics* **13(10)**: 393-399; Carver and Stubbs, 1997, *Genome Research* **7**:1123-1137; all of which are incorporated by reference herein).

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides  
15 which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize  
20 overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

25 The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as  
30 stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

	Stringency Condition	Polynucleotide Hybrid	Hybrid Length (bp) <sup>‡</sup>	Hybridization Temperature and Buffer <sup>†</sup>	Wash Temperature and Buffer <sup>†</sup>
5	A	DNA:DNA	≥ 50	65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide	65°C; 0.3xSSC
	B	DNA:DNA	<50	T <sub>B</sub> *; 1xSSC	T <sub>B</sub> *; 1xSSC
	C	DNA:RNA	≥ 50	67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide	67°C; 0.3xSSC
	D	DNA:RNA	<50	T <sub>D</sub> *; 1xSSC	T <sub>D</sub> *; 1xSSC
	E	RNA:RNA	≥ 50	70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide	70°C; 0.3xSSC
	F	RNA:RNA	<50	T <sub>F</sub> *; 1xSSC	T <sub>F</sub> *; 1xSSC
10	G	DNA:DNA	≥ 50	65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide	65°C; 1xSSC
	H	DNA:DNA	<50	T <sub>H</sub> *; 4xSSC	T <sub>H</sub> *; 4xSSC
	I	DNA:RNA	≥ 50	67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide	67°C; 1xSSC
	J	DNA:RNA	<50	T <sub>J</sub> *; 4xSSC	T <sub>J</sub> *; 4xSSC
	K	RNA:RNA	≥ 50	70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide	67°C; 1xSSC
	L	RNA:RNA	<50	T <sub>L</sub> *; 2xSSC	T <sub>L</sub> *; 2xSSC
15	M	DNA:DNA	≥ 50	50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide	50°C; 2xSSC
	N	DNA:DNA	<50	T <sub>N</sub> *; 6xSSC	T <sub>N</sub> *; 6xSSC
	O	DNA:RNA	≥ 50	55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide	55°C; 2xSSC
	P	DNA:RNA	<50	T <sub>P</sub> *; 6xSSC	T <sub>P</sub> *; 6xSSC
	Q	RNA:RNA	≥ 50	60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide	60°C; 2xSSC
	R	RNA:RNA	<50	T <sub>R</sub> *; 4xSSC	T <sub>R</sub> *; 4xSSC

<sup>‡</sup>: The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

<sup>†</sup>: SSPE (1xSSPE is 0.15M NaCl, 10mM NaH<sub>2</sub>PO<sub>4</sub>, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

\*T<sub>B</sub> - T<sub>R</sub>: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T<sub>m</sub>) of the hybrid, where T<sub>m</sub> is determined according to the following equations. For hybrids less than 18 base pairs in length, T<sub>m</sub>(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T<sub>m</sub>(°C) = 81.5 + 16.6(log<sub>10</sub>[Na<sup>+</sup>]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na<sup>+</sup>] is the concentration of sodium ions in the hybridization buffer ([Na<sup>+</sup>] for 1xSSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds.,  
5 John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or  
10 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide of the invention may be operably linked to an  
15 expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined herein "operably  
20 linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the  
25 protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

30 Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial

strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLabs (Beverly, MA), Pharmacia (Piscataway, NJ) and Invitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to  
5 provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which  
10 are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by  
15 virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement,  
20 insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement,  
25 insertion or deletion retains the desired activity of the protein.  
30

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art

given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

## 5 USES AND BIOLOGICAL ACTIVITY

The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration  
10 or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

### Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research  
15 community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags  
20 (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting  
25 and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the  
30 polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris *et al.*, 1993, *Cell* 75: 791-803 and in Rossi *et al.*, 1997, *Proc. Natl. Acad. Sci. USA* 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine  
5 levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the  
10 protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent  
15 grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to  
20 Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

#### Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein  
25 or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention  
30 can be added to the medium in or on which the microorganism is cultured.

#### Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may

induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is  
5 evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured  
10 by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter  
15 7, Immunologic studies in Humans); Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bertagnolli et al., *J. Immunol.* 145:1706-1712, 1990; Bertagnolli et al., *Cellular Immunology* 133:327-341, 1991; Bertagnolli, et al., *J. Immunol.* 149:3778-3783, 1992; Bowman et al., *J. Immunol.* 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node  
20 cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon  $\gamma$ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic  
25 cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., *J. Exp. Med.* 173:1205-1211, 1991; Moreau et al., *Nature*  
30 336:690-692, 1988; Greenberger et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., *Proc. Natl. Acad. Sci. U.S.A.* 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols*

in *Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

- 5            Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience  
10 (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

15

#### Immune Stimulating or Suppressing Activity

- A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune  
20 deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious  
25 diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the  
30 treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus,

myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for  
5 example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the  
10 induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is  
15 distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without  
20 limitation B lymphocyte antigen functions (such as , for example, B7)), *e.g.*, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated  
25 through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-  
30 1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to

anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of  
5 B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been  
10 used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development  
15 of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the  
20 activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce  
25 antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/*lpr/lpr* mice or NZB hybrid mice,  
30 murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy.

Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a

cytoplasmic-domain truncated portion) of an MHC class I  $\alpha$  chain protein and  $\beta_2$  microglobulin protein or an MHC class II  $\alpha$  chain protein and an MHC class II  $\beta$  chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having  
5 the activity of a B lymphocyte antigen (*e.g.*, B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated  
10 antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

15 Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, *Immunologic studies in Humans*); Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Takai et al., *J. Immunol.* 140:508-512, 1988; Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 20 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bowman et al., *J. Virology* 61:1992-1998; Takai et al., *J. Immunol.* 140:508-512, 1988; Bertagnolli et al., *Cellular Immunology* 133:327-341, 1991; Brown et al., *J. Immunol.* 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described  
30 in: Maliszewski, *J. Immunol.* 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation,

those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai  
 5 et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology  
 10 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz  
 15 et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993;  
 20 Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood  
 25 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.

#### Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even  
 30 marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid

precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. *Cellular Biology* 15:141-151, 1995; Keller et al., *Molecular and Cellular Biology* 13:473-486, 1993; McClanahan et al., *Blood* 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., *Proc. Natl. Acad. Sci. USA* 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., *Experimental Hematology* 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long

term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

#### Tissue Growth Activity

A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as

well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also  
5 useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The  
10 compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural  
15 cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and  
20 localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting  
25 from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

30 It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation

of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium ).

Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

#### Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin  $\alpha$  family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin- $\beta$  group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., *Endocrinology* 91:562-572, 1972; Ling et al., *Nature* 321:779-782, 1986; Vale et al., *Nature* 321:776-779, 1986; Mason et al., *Nature* 318:659-663, 1985; Forage et al., *Proc. Natl. Acad. Sci. USA* 83:3091-3095, 1986.

#### Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. *J. Clin. Invest.* 95:1370-1376, 1995; Lind et al.

APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

#### Hemostatic and Thrombolytic Activity

5 A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting  
10 formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke)).

The activity of a protein of the invention may, among other means, be measured by the following methods:

15 Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

#### Receptor/Ligand Activity

20 A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands,  
25 receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant  
30 receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static  
5 conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenberg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

#### 10        Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the  
15 inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic  
20 inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

25

#### Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to  
30 tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved

extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only  
5 itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells  
10 become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas  
15 to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed  
20 in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the  
25 inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block  
30 the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

#### Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

#### Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s);

effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic  
5 lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another  
10 material or entity which is cross-reactive with such protein.

### ADMINISTRATION AND DOSING

A protein of the present invention (from whatever source derived, including  
15 without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the  
20 effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem  
25 cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included  
30 in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

5           The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following  
10 presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin  
15 and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other  
20 pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the  
25 art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is  
30 sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to

a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to  
5 pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The  
10 pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone.  
15 Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not  
20 increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01  $\mu$ g to about 100 mg (preferably about 0.1mg to about 10 mg, more preferably about 0.1  $\mu$ g to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and  
25 the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous  
30 therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the

carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10 (1987). Monoclonal antibodies binding to the protein of the invention may be  
5 useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting  
10 and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When  
15 administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also  
20 optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the  
25 developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular  
30 application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins

or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and  
5 tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns.  
10 In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose,  
15 ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20  
20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

25 In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- $\alpha$  and TGF- $\beta$ ), and insulin-like growth factor (IGF).

30 The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering

various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary  
5 with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline  
10 labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without  
15 limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

20 Patent and literature references cited herein are incorporated by reference as if fully set forth.

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:
  - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
  - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265;
  - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265;
  - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bd306\_7 deposited under accession number ATCC 98599;
  - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bd306\_7 deposited under accession number ATCC 98599;
  - (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone bd306\_7 deposited under accession number ATCC 98599;
  - (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone bd306\_7 deposited under accession number ATCC 98599;
  - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
  - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;
  - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
  - (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).
2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.
3. A host cell transformed with the polynucleotide of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:
  - (a) growing a culture of the host cell of claim 3 in a suitable culture medium; and

- (b) purifying said protein from the culture.
- 6. A protein produced according to the process of claim 5.
- 7. An isolated polynucleotide encoding the protein of claim 6.
- 8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone bd306\_7 deposited under accession number ATCC 98599.
- 9. A protein comprising an amino acid sequence selected from the group consisting of:
  - (a) the amino acid sequence of SEQ ID NO:2;
  - (b) the amino acid sequence of SEQ ID NO:2 from amino acid 148 to amino acid 189;
  - (c) fragments of the amino acid sequence of SEQ ID NO:2 comprising eight consecutive amino acids of SEQ ID NO:2; and
  - (d) the amino acid sequence encoded by the cDNA insert of clone bd306\_7 deposited under accession number ATCC 98599;the protein being substantially free from other mammalian proteins.
- 10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.
- 11. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acid 148 to amino acid 189.
- 12. A composition comprising the protein of claim 9 and a pharmaceutically acceptable carrier.
- 13. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:
  - (a) a process comprising the steps of:
    - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
      - (aa) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and
      - (ab) the nucleotide sequence of the cDNA insert of clone bd306\_7 deposited under accession number ATCC 98599; and

- (ii) hybridizing said probe(s) to human DNA; and
- (iii) isolating the DNA polynucleotide detected with the probe(s);

and

- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and
    - (bb) the nucleotide sequence of the cDNA insert of clone bd306\_7 deposited under accession number ATCC 98599; and
  - (ii) hybridizing said primer(s) to human DNA;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

- (v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1;
- (w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 63 to nucleotide 1265; and
- (x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 132 to nucleotide 1265.

- 14. An isolated polynucleotide produced according to the process of claim 13.
- 15. An isolated polynucleotide comprising the polynucleotide of claim 14.
- 16. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 982 to nucleotide 2118;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 1042 to nucleotide 2118;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 621 to nucleotide 1248;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fj283\_6 deposited under accession number ATCC xxxxx;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fj283\_6 deposited under accession number ATCC xxxxx;
- (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone fj283\_6 deposited under accession number ATCC xxxxx;
- (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone fj283\_6 deposited under accession number ATCC xxxxx;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4; and
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above.

17. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:4;
  - (b) fragments of the amino acid sequence of SEQ ID NO:4 comprising eight consecutive amino acids of SEQ ID NO:4; and
  - (c) the amino acid sequence encoded by the cDNA insert of clone fj283\_6 deposited under accession number ATCC xxxxx;
- the protein being substantially free from other mammalian proteins.

18. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone fk317\_3 deposited under accession number ATCC 98599;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone fk317\_3 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
- (f) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:6;
- (g) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; and
- (h) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(f).

19. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:6;
  - (b) the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 72;
  - (c) fragments of the amino acid sequence of SEQ ID NO:6 comprising eight consecutive amino acids of SEQ ID NO:6; and
  - (d) the amino acid sequence encoded by the cDNA insert of clone fk317\_3 deposited under accession number ATCC 98599;
- the protein being substantially free from other mammalian proteins.

20. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and
    - (ab) the nucleotide sequence of the cDNA insert of clone fk317\_3 deposited under accession number ATCC 98599; and
  - (ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the probe(s);  
and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(bb) the nucleotide sequence of the cDNA insert of clone fk317\_3 deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

(v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 259 to nucleotide 624.

21. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone k213\_2x deposited under accession number ATCC 98599;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone k213\_2x deposited under accession number ATCC 98599;

(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone k213\_2x deposited under accession number ATCC 98599;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone k213\_2x deposited under accession number ATCC 98599;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:8;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

22. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:8;

(b) fragments of the amino acid sequence of SEQ ID NO:8 comprising eight consecutive amino acids of SEQ ID NO:8; and

(c) the amino acid sequence encoded by the cDNA insert of clone k213\_2x deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

23. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and

(ab) the nucleotide sequence of the cDNA insert of clone k213\_2x deposited under accession number ATCC 98599; and

(ii) hybridizing said probe(s) to human DNA; and

(iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and

(bb) the nucleotide sequence of the cDNA insert of clone k213\_2x deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

(v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7;

(w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 357 to nucleotide 578; and

(x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 471 to nucleotide 578.

24. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone na316\_1 deposited under accession number ATCC 98599;

- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone na316\_1 deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone na316\_1 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone na316\_1 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:10;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

25. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- (b) fragments of the amino acid sequence of SEQ ID NO:10 comprising eight consecutive amino acids of SEQ ID NO:10; and
- (c) the amino acid sequence encoded by the cDNA insert of clone na316\_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

26. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and
    - (ab) the nucleotide sequence of the cDNA insert of clone na316\_1 deposited under accession number ATCC 98599; and
  - (ii) hybridizing said probe(s) to human DNA; and
  - (iii) isolating the DNA polynucleotide detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and

(bb) the nucleotide sequence of the cDNA insert of clone na316\_1 deposited under accession number ATCC 98599; and

(ii) hybridizing said primer(s) to human DNA;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

(v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9;

(w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 332 to nucleotide 598; and

(x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 458 to nucleotide 598.

27. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone nf93\_20 deposited under accession number ATCC 98599;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone nf93\_20 deposited under accession number ATCC 98599;

(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone nf93\_20 deposited under accession number ATCC 98599;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone nf93\_20 deposited under accession number ATCC 98599;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:12;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

28. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:12;

(b) fragments of the amino acid sequence of SEQ ID NO:12 comprising eight consecutive amino acids of SEQ ID NO:12; and

(c) the amino acid sequence encoded by the cDNA insert of clone nf93\_20 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

29. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and

(ab) the nucleotide sequence of the cDNA insert of clone nf93\_20 deposited under accession number ATCC 98599; and

- (ii) hybridizing said probe(s) to human DNA; and
  - (iii) isolating the DNA polynucleotide detected with the probe(s);
- and

- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and
    - (bb) the nucleotide sequence of the cDNA insert of clone nf93\_20 deposited under accession number ATCC 98599; and
  - (ii) hybridizing said primer(s) to human DNA;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

- (v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11;
- (w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 354 to nucleotide 986; and
- (x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 408 to nucleotide 986.

30. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821;

- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone np164\_1 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone np164\_1 deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone np164\_1 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone np164\_1 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:14;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

31. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;
- (b) fragments of the amino acid sequence of SEQ ID NO:14 comprising eight consecutive amino acids of SEQ ID NO:14; and
- (c) the amino acid sequence encoded by the cDNA insert of clone np164\_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

32. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and

- (ab) the nucleotide sequence of the cDNA insert of clone np164\_1 deposited under accession number ATCC 98599; and
- (ii) hybridizing said probe(s) to human DNA; and
- (iii) isolating the DNA polynucleotide detected with the probe(s);

and

- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and
    - (bb) the nucleotide sequence of the cDNA insert of clone np164\_1 deposited under accession number ATCC 98599; and
  - (ii) hybridizing said primer(s) to human DNA;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

- (v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13;
- (w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 301 to nucleotide 1821; and
- (x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 1381 to nucleotide 1821.

33. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 532 to nucleotide 537;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pe204\_1 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pe204\_1 deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone pe204\_1 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone pe204\_1 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:16;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

34. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:16;
- (b) fragments of the amino acid sequence of SEQ ID NO:16 comprising eight consecutive amino acids of SEQ ID NO:16; and
- (c) the amino acid sequence encoded by the cDNA insert of clone pe204\_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

35. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- (aa) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and
- (ab) the nucleotide sequence of the cDNA insert of clone pe204\_1 deposited under accession number ATCC 98599; and
- (ii) hybridizing said probe(s) to human DNA; and
- (iii) isolating the DNA polynucleotide detected with the probe(s);

and

- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and
    - (bb) the nucleotide sequence of the cDNA insert of clone pe204\_1 deposited under accession number ATCC 98599; and
  - (ii) hybridizing said primer(s) to human DNA;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

- (v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and
- (w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 148 to nucleotide 537.

36. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109;

- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ya1\_1 deposited under accession number ATCC 98599;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ya1\_1 deposited under accession number ATCC 98599;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone ya1\_1 deposited under accession number ATCC 98599;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone ya1\_1 deposited under accession number ATCC 98599;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:18;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

37. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
- (b) fragments of the amino acid sequence of SEQ ID NO:18 comprising eight consecutive amino acids of SEQ ID NO:18; and
- (c) the amino acid sequence encoded by the cDNA insert of clone ya1\_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

38. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and

- (ab) the nucleotide sequence of the cDNA insert of clone ya1\_1 deposited under accession number ATCC 98599; and
- (ii) hybridizing said probe(s) to human DNA; and
- (iii) isolating the DNA polynucleotide detected with the probe(s);

and

- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and
    - (bb) the nucleotide sequence of the cDNA insert of clone ya1\_1 deposited under accession number ATCC 98599; and
  - (ii) hybridizing said primer(s) to human DNA;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

- (v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:17 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17;
- (w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 24 to nucleotide 1109; and
- (x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 1050 to nucleotide 1109.

39. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734;

(d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yb8\_1 deposited under accession number ATCC 98599;

(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yb8\_1 deposited under accession number ATCC 98599;

(g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone yb8\_1 deposited under accession number ATCC 98599;

(h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone yb8\_1 deposited under accession number ATCC 98599;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:20;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

40. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:20;

(b) the amino acid sequence of SEQ ID NO:20 from amino acid 70 to amino acid 236;

(c) fragments of the amino acid sequence of SEQ ID NO:20 comprising eight consecutive amino acids of SEQ ID NO:20; and

(d) the amino acid sequence encoded by the cDNA insert of clone yb8\_1 deposited under accession number ATCC 98599;

the protein being substantially free from other mammalian proteins.

41. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
  - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (aa) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and
    - (ab) the nucleotide sequence of the cDNA insert of clone yb8\_1 deposited under accession number ATCC 98599; and
  - (ii) hybridizing said probe(s) to human DNA; and
  - (iii) isolating the DNA polynucleotide detected with the probe(s);

and

- (b) a process comprising the steps of:
  - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
    - (ba) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and
    - (bb) the nucleotide sequence of the cDNA insert of clone yb8\_1 deposited under accession number ATCC 98599; and
  - (ii) hybridizing said primer(s) to human DNA;
  - (iii) amplifying human DNA sequences; and
  - (iv) isolating the polynucleotide product of step (b)(iii);

wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

- (v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19;
- (w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 27 to nucleotide 734;
- (x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734, to a nucleotide sequence corresponding to

the 3' end of said sequence of SEQ ID NO:19 from nucleotide 270 to nucleotide 734; and

(y) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 85 to nucleotide 1604.

FIGURE 1A





FIGURE 1B



## SEQUENCE LISTING

<110> Jacobs, Kenneth  
 McCoy, John M.  
 LaVallie, Edward R.  
 Collins-Racie, Lisa A.  
 Evans, Cheryl  
 Merberg, David  
 Treacy, Maurice  
 Agostino, Michael J.  
 Steininger II, Robert J.  
 Wong, Gordon G.  
 Clark, Hilary  
 Fechtel, Kim  
 Genetics Institute, Inc.

<120> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

<130> 6055A

<140>

<141>

<160> 32

<170> PatentIn Ver. 2.0

<210> 1

<211> 3871

<212> DNA

<213> Homo sapiens

<400> 1

```

tttccctctc cctcccccctt tcccttcctt cgtecccttc ttccttcctt togcgcggcg 60
cgatggagcc ggggcgcgcg ggggcgcgcg cgctgctagc gctgctgtgc gtggcctgcg 120
cgctgcgcgc cgggcgcgcg caatacgaac gctacagctt ccgcagcttc ccacgggacg 180
agctgatgcc gctcgagtcg gcctaccggc acgcgctgga caagtacagc ggcgagcact 240
gggcccagag cstkggctac ctggagatca gcctgcggct gcacgccttg ctgcgcgcaca 300
gcgaggccct ctgccaccgc aactgcagcg ccgcgcgcga gcccagagcc gccgcgcggc 360
tcgccagcta tcccgagctg cgccctcttc ggggcctgct gcgcgcgcgc cactgcctca 420
agcgtgcaa gcagggcctg ccagccttcc gccagtccca gccagccgc gaggtgctgg 480
cggacttcca gcgcgcgcag ccctacaagt tccctgagtt cgttacttcc aaggcaaata 540
atctccccc aaacatcgcc gctgctcaca cctttctact gaagcatcct gatgacgaaa 600
tgatgaagag gaacatggca tattataaga gcctgcctgg tgccgaggac tacattaaag 660
acctggaaac caagtcatat gaaagcctgt tcatccgagc agtgccggca tacaacgggtg 720
agaactggag aacatccatc acagacatgg agctggccct tcccgacttc ttcaaagcct 780
tttacgagtg tctcgagcc tcgaggggtt ccaggagat caaggacttc aaggatttct 840
acctttccat agcagatcat tatgtagaag ttctggaatg caaaatacag tgtgaagaga 900
acctcacccc agttatagga ggctatccgg ttgagaaatt tgtggctacc atgtatcatt 960
acttgagtt tgctattat aagttgaacg acctgaagaa tgcagcccc tgtgcagtca 1020
gctatctgct ctttgatcag aatgacaagg tcatgcagca gaacctggtg tattaccagt 1080
accacagggg cacttggggc ctctcgatg agcacttcca gccagacct gaagcagttc 1140
agttctttaa tgtgaccaca ctccagaagg agctgtatga ctttgctaag gaaaatataa 1200
tggatgatga tgagggagaa gttgtggaat atgtggatga cctcttgga ctggaggaga 1260
ccagctagcc cacagcaacc aaagagactt cctcttggcg ttcaggaaac acagattctt 1320
tgtcttttcc ccaacagccc aggcgtgttg tacctcagag ccttctcttt actctccaaa 1380
gtgaaagggg agccccgctc tctctaactg catgtcatca ggggtgagcc tgcctttcct 1440
atcttcacac ctgccacctc atgttcacac ctatctttct cacctttttt ttgagatgga 1500
gtctcgctct cttgcccagg ctggagtgc atggcacgtt ctgagctcac tgcaacctcc 1560
gcctcttggg ttcaagcaat tctgctgcat cagcctcccg agtacctggg attacaggca 1620

```

```

tgtgccacca cgcccggtta attttgtatt tttagtagag acgggggttt gccatgttgg 1680
ccaggctggg ctggaactct tgacttcaga tgatccatct gccttggcct cccacagtgc 1740
tggtgattaca ggcgtgagcc accatgcccg gcctctttct cacttttaca cctgtcttct 1800
tctcctcaca tctgttttca cacttcate cctgtcttcc tcatgttcac acttgtcttc 1860
cccatgttca tagctgcctt tcttaccatt ttggtttgaa gggcagtctt ctctggcttg 1920
tttttttgtt ttcccagaa aatcagtatt attttttaaa taagaaaaac attcctagaa 1980
gatgataatt gtgaaaacct cctttggctt atttgccttt ccagatttta gtctccttcc 2040
tccccatccg ggaaagatgg tggaaagacat aggctaaatt tctccagcct cacaatgggc 2100
ttcacttggg ctgacttgta ccaattctag caccactga aaaacaagt gagtagagag 2160
tgtagagtgc agaaatgtgg cttttgcccc actttgcac tccaaaatta caacgggttg 2220
ccgatcccat ttgaggacaa tgcttagtta taagtctccg agttggaaaa ggaagaaagc 2280
cagagctgtc tagtttcatt cattctttca gtaaatatatt attgagtacc tactgtgtgc 2340
taggcattga cctgggaact agagatactt cacagaataa cagggaaagt tccctgtgct 2400
catggagctt acattctaca gggagaaaga gatagccaat acataggaat aaatatatac 2460
aaggatcat gtagtataa ttgctgtgga gaaaaataaa gcaggggagg gtagtaagaa 2520
tcttgagat gaggtctgag ttttaaatgg ggcctcactg ggaatgtgac gttgagcaga 2580
gacgttaggg aagtggatcc tggacaaggc attccaggca gaggaacaag atgtgcactg 2640
ccccaaagtg agaacttgct ctacgtgggc aggaagagc agggagacca agcagagtcg 2700
tggtcagggg tagaatggaa ggagagggcg ctggggagga caggtggttg agggccttg 2760
cttctgctaa gtgagatggg aaccactgga gggtttgaa agaggagtgc cttgattgat 2820
ttatatattt caagggtcat tctagctgca atattgtgaa aaactttagt ggacaagggc 2880
agaaggaaga gggaagacct gttaggaagc tactgcaagg ttccaggett gggcctgggc 2940
cacagcaaca gcagtggta aatatctaga tttattttga aaagagccaa taggatttgc 3000
tgagagtttg aatgtggagt gtaagagaag gaagagttaa tgatgacatt aaggtttttg 3060
gcctgaatag caggaagat ggagttacca gttactgaaa tagggaagga tgggctgggt 3120
aagtaaggaa tttggtgcaa agcaggtctg ctgtggttg aatgggagg tctggctgca 3180
aatcaaagt gagattctct caggtcaggt ctgcagcaga gctcgagaca gggatctgaa 3240
tgcaacttgg ttattgttgg ggtgctctc agaaggaacc tgtgaaagcc ttatcagtc 3300
atttatttgg tgtgagaagt tctctgggag tgtgggtaca tttgaaggca agtgacttca 3360
gttgagggca agtctctgga aaagaggctg taggcactcg gcagctacca tgcgtggtg 3420
tgtgttgggg gtgggggttc tgggcactgg ctgtgtgaag ggaatctggc gggcaccaca 3480
gcgcccccta ctgaaccatc agcatgtcag tggcatllaa agccatgcag ctggaggggc 3540
cactgagatt gtctctgagt attactgaga agcaacagaa aagagccatg gatggagccc 3600
ttgggctctc tgggaaatgg gaaatcagcc aaaggactga gaaggagtta ccttaaggtc 3660
agagaaaacc aagagagtgt ggtgttcttg aagctgagct ttctttattc aacctcattc 3720
ccttctccaa ataagccact tgtgtagttg ggcccccca gggttgaagg caagaggaga 3780
aaggcacagc gtttgggaaa caagactttt cctgcaatag cctgggaagg aataaaaagga 3840
tagagtgtta aaataaaaaa aaaaaaaaaa a 3871

```

<210> 2  
 <211> 401  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> UNSURE  
 <222> (64)

<400> 2  
 Met Glu Pro Gly Arg Arg Gly Ala Ala Ala Leu Leu Ala Leu Leu Cys  
 1 5 10 15  
 Val Ala Cys Ala Leu Arg Ala Gly Arg Ala Gln Tyr Glu Arg Tyr Ser  
 20 25 30  
 Phe Arg Ser Phe Pro Arg Asp Glu Leu Met Pro Leu Glu Ser Ala Tyr  
 35 40 45  
 Arg His Ala Leu Asp Lys Tyr Ser Gly Glu His Trp Ala Glu Ser Xaa  
 50 55 60

Gly Tyr Leu Glu Ile Ser Leu Arg Leu His Arg Leu Leu Arg Asp Ser  
 65 70 75 80  
 Glu Ala Phe Cys His Arg Asn Cys Ser Ala Ala Pro Gln Pro Glu Pro  
 85 90 95  
 Ala Ala Gly Leu Ala Ser Tyr Pro Glu Leu Arg Leu Phe Gly Gly Leu  
 100 105 110  
 Leu Arg Arg Ala His Cys Leu Lys Arg Cys Lys Gln Gly Leu Pro Ala  
 115 120 125  
 Phe Arg Gln Ser Gln Pro Ser Arg Glu Val Leu Ala Asp Phe Gln Arg  
 130 135 140  
 Arg Glu Pro Tyr Lys Phe Leu Gln Phe Ala Tyr Phe Lys Ala Asn Asn  
 145 150 155 160  
 Leu Pro Lys Ala Ile Ala Ala Ala His Thr Phe Leu Leu Lys His Pro  
 165 170 175  
 Asp Asp Glu Met Met Lys Arg Asn Met Ala Tyr Tyr Lys Ser Leu Pro  
 180 185 190  
 Gly Ala Glu Asp Tyr Ile Lys Asp Leu Glu Thr Lys Ser Tyr Glu Ser  
 195 200 205  
 Leu Phe Ile Arg Ala Val Arg Ala Tyr Asn Gly Glu Asn Trp Arg Thr  
 210 215 220  
 Ser Ile Thr Asp Met Glu Leu Ala Leu Pro Asp Phe Phe Lys Ala Phe  
 225 230 235 240  
 Tyr Glu Cys Leu Ala Ala Cys Glu Gly Ser Arg Glu Ile Lys Asp Phe  
 245 250 255  
 Lys Asp Phe Tyr Leu Ser Ile Ala Asp His Tyr Val Glu Val Leu Glu  
 260 265 270  
 Cys Lys Ile Gln Cys Glu Glu Asn Leu Thr Pro Val Ile Gly Gly Tyr  
 275 280 285  
 Pro Val Glu Lys Phe Val Ala Thr Met Tyr His Tyr Leu Gln Phe Ala  
 290 295 300  
 Tyr Tyr Lys Leu Asn Asp Leu Lys Asn Ala Ala Pro Cys Ala Val Ser  
 305 310 315 320  
 Tyr Leu Leu Phe Asp Gln Asn Asp Lys Val Met Gln Gln Asn Leu Val  
 325 330 335  
 Tyr Tyr Gln Tyr His Arg Asp Thr Trp Gly Leu Ser Asp Glu His Phe  
 340 345 350  
 Gln Pro Arg Pro Glu Ala Val Gln Phe Phe Asn Val Thr Thr Leu Gln  
 355 360 365  
 Lys Glu Leu Tyr Asp Phe Ala Lys Glu Asn Ile Met Asp Asp Asp Glu  
 370 375 380

Gly Glu Val Val Glu Tyr Val Asp Asp Leu Leu Glu Leu Glu Glu Thr  
 385 390 395 400

Ser

<210> 3

<211> 3637

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (1582)

<400> 3

```

tttttttttt ttttttttta agaagaaggt ccaaatcaat aggtctttta ttgcatcatt 60
taaatatcac aagtaggtct taagtgtcat ctggcatctt ctttctgtag ccaggtaact 120
cttagatctt attcatcagc ctgctgaaca gtctcttttt cagagacata gataccatcc 180
aaaaatttcc tgatattcct gtttttaact gttgtggctt gctgaatcaa agccgctgaa 240
tttgaaccaa gctcaatgtc atcccgattg agtaccagct cccactgcc ctgagggcgg 300
gccggcctgc ggcggaggga aaaaggaaga ggagaaggaa attgtcccg aatccctgcag 360
tctttctgta ggttgccgca caacgccagg caaaagaaga ggaagggaatt taatcctaatt 420
cggtggaggt cgatttgagg gtctgctgta gcagggtggct ccgcttgaag cgagggagga 480
agtttccctcc gatcagtaga gattggaaag attgttggga gtggcacacc actagggaaa 540
agaagaaggg gcgaactgct tgtcttgagg aggtcaaccc ccagaatcag ctcttctgtgc 600
cttgaagtgg ctgaagacga tcacctcca caggcttgag cccagtcca cagccttctt 660
ccccagcct gagtgtactac tctattcctt ggtccctgct attgtcgggg acgattgcat 720
gggtacgcgc aggaaaagtag gctgggtgac cgcaggcctg gtgattgggg ctggcgctcg 780
ctattgcatt tatagactga ctaggggag aaaaacagaac aaggaaaaaa tggctgaggg 840
tggatctggg gatgtggatg atgctgggga ctgttctggg gccaggtata atgactggtc 900
tgatgatgat gatgacagca atgagagcaa gattatagta tggtagccac cttgggctcg 960
gattgggact gaagctggaa ccagaactag gccaggggca agggccaggg ctaccggggc 1020
acgtctggct gtccagaaac gggcttcccc caattcagat gataccgttt tgtccctcca 1080
agagctacaa aaggttcttt gcttgggtga gatgtctgaa aagccttata ttcttgaagc 1140
agctttaatt gctctgggta acaatgctgc ttatgcattt aacagagata ttattcgtga 1200
tctgggtggg tctcccaattg tcgcaaagat tctcaatact cgggatccca tagttaagga 1260
aaaggtcttta attgtcctga ataacttgag tgtgaatgct gaaaatcagc gcaggcttaa 1320
agtatacatg aatcaagtgt gtgatgacac aatcacttct cgcttgaact catctgtgca 1380
gcttgtctgga ctgagattgc ttacaaatat gactgttact aatgagtatc agcacatgct 1440
tgctaattcc atttctgact tttttcgttt attttcagcg ggaaatgaag aaaccaaact 1500
tcagggttctg aaactccttt tgaatttggc tgaaaatcca gccatgacta gggaactgct 1560
cagggcccaa gtaccatctt cncctgggctc cctctttaat aagaaggaga acaaagaagt 1620
tattcttaaa cttctgggtca tatttgagaa cataaatgat aatttcaaat gggaagaaaa 1680
tgaacctact cagaatcaat tcggtgaagg ttcacttttt ttctttttta aagaatttca 1740
agtgtgtgct gataagggtc tgggaataga aagtcaccat gatttttttg tgaaagtaaa 1800
agttggaaaa ttcatggcca aacttgctga acatatgttc ccaaagagcc aggaataaca 1860
ccttgatttt gtaattttaga agcaacacac attgtaaact attcattttc tccaccttgt 1920
ttatatggta aaggaatcct ttcagctgcc agttttgaat aatgaatatc atattgtatc 1980
atcaatgctg atattttaat gagttgtctt ttagggttaa gatggataaa tgaatatcac 2040
tacttgttct gaaaacatgt ttgttgcctt ttatctcgct gccatgattg aaatattttg 2100
ctattttctt tgcataagtg acagtgaacc aattcatcat gagtaagctc cttctgtgca 2160
ttttcattga ttttaatttg gtatcatcaa taaaattgta tgtaaatgct ggaaagaaaa 2220
aaagaagaaa gaaagaaacc atccctgtcc ttcagtttat aatctagtgg gagagataag 2280
aaacgtacaa accaaaagat aacagatat ctgaagcatg tactcattgt cagatgttcc 2340
ctctgagagc acagaggagg caaaagcttc tgtgggatgt gctagtcggc taaagcttca 2400
cagaggaggt ggcaattgaa aatgagtcct gaatggggta ggggtggtag ggaattccat 2460
gagacaagac aaggggggca tgggtgtgaga aaggcatgga agtaggaacc ctcttctcat 2520

```

```

gacaggagat cattctgctt agagtggaga gtgtggagag tgggagtaga taatttttga 2580
aagctgggtg aagccagttg tggagaattg tttgaatatt atcccattga ataccagag 2640
ccactaaatc tttttttact agaaaataat tgggggccat atgaaagtct ctattactga 2700
gtagtgtcaa tgagggtgtg gcaaaatgga gcctttcaca tcctagtggg ggccatttgg 2760
taatacacag ataagcctta aactatgtaa acccttgtcc taaggaagta attgaataat 2820
tgcccaaaga ttgtatgtat gaggtgttc atcccagcac tgtctaagct agtaaaaatt 2880
ggaaacaatt taagtatcta gcacattgga ttggttataa agcaaggaat gttcacacag 2940
taggatatta taagtatgct gatggaaatc tatattgcca ggaaaagcta ttcattatgc 3000
gttgtgaagt cagaaagtaa aaaagggtag atagaagtat tcgaagtata gttccatttt 3060
ttgagactaa taaaacatat gtttaaaagg acactaaaaa ctggagttat agatatccag 3120
atagaaacag tagttatctt tgggtagaag aataatgagt gatctttact tttttacttt 3180
ttattcatct ttgtgttttt atttatctaa aatgggtatt gatttttagg acggttttga 3240
aaaagaaaag tgttgggaat gaagcaagtg attgattgga aaacatactg aatggaagaa 3300
atatttagat taaaaatgag gtaggttgaa gttttctctc tgaaatgata gataaatggt 3360
gaagataagg cttattgtga ggattcagtg aggtaatata tgcaaagtac ttacaatggt 3420
ctggcacata gtaattaatt aagaaaatcg agcaccctta attacctaga atgcagggtt 3480
gttagttttt tggttgactt ttgttttget ggggcattct gccatgtttt agtgtcattt 3540
aataaataat agtaacaata aaggttaaca tttattaagt gaaaaaaaaa aaaaaaaaaa 3600
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 3637

```

&lt;210&gt; 4

&lt;211&gt; 379

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

```

Met Gly Tyr Ala Arg Lys Val Gly Trp Val Thr Ala Gly Leu Val Ile
  1                      5                      10                      15

```

```

Gly Ala Gly Ala Cys Tyr Cys Ile Tyr Arg Leu Thr Arg Gly Arg Lys
      20                      25                      30

```

```

Gln Asn Lys Glu Lys Met Ala Glu Gly Gly Ser Gly Asp Val Asp Asp
      35                      40                      45

```

```

Ala Gly Asp Cys Ser Gly Ala Arg Tyr Asn Asp Trp Ser Asp Asp Asp
      50                      55                      60

```

```

Asp Asp Ser Asn Glu Ser Lys Ser Ile Val Trp Tyr Pro Pro Trp Ala
      65                      70                      75                      80

```

```

Arg Ile Gly Thr Glu Ala Gly Thr Arg Thr Arg Ala Arg Ala Arg Ala
      85                      90                      95

```

```

Arg Ala Thr Arg Ala Arg Leu Ala Val Gln Lys Arg Ala Ser Pro Asn
     100                      105                      110

```

```

Ser Asp Asp Thr Val Leu Ser Pro Gln Glu Leu Gln Lys Val Leu Cys
     115                      120                      125

```

```

Leu Val Glu Met Ser Glu Lys Pro Tyr Ile Leu Glu Ala Ala Leu Ile
     130                      135                      140

```

```

Ala Leu Gly Asn Asn Ala Ala Tyr Ala Phe Asn Arg Asp Ile Ile Arg
     145                      150                      155                      160

```

```

Asp Leu Gly Gly Leu Pro Ile Val Ala Lys Ile Leu Asn Thr Arg Asp
     165                      170                      175

```

```

Pro Ile Val Lys Glu Lys Ala Leu Ile Val Leu Asn Asn Leu Ser Val

```

180	185	190
Asn Ala Glu Asn Gln Arg Arg Leu Lys Val Tyr Met Asn Gln Val Cys		
195	200	205
Asp Asp Thr Ile Thr Ser Arg Leu Asn Ser Ser Val Gln Leu Ala Gly		
210	215	220
Leu Arg Leu Leu Thr Asn Met Thr Val Thr Asn Glu Tyr Gln His Met		
225	230	235 240
Leu Ala Asn Ser Ile Ser Asp Phe Phe Arg Leu Phe Ser Ala Gly Asn		
245	250	255
Glu Glu Thr Lys Leu Gln Val Leu Lys Leu Leu Leu Asn Leu Ala Glu		
260	265	270
Asn Pro Ala Met Thr Arg Glu Leu Leu Arg Ala Gln Val Pro Ser Ser		
275	280	285
Leu Gly Ser Leu Phe Asn Lys Lys Glu Asn Lys Glu Val Ile Leu Lys		
290	295	300
Leu Leu Val Ile Phe Glu Asn Ile Asn Asp Asn Phe Lys Trp Glu Glu		
305	310	315 320
Asn Glu Pro Thr Gln Asn Gln Phe Gly Glu Gly Ser Leu Phe Phe Phe		
325	330	335
Leu Lys Glu Phe Gln Val Cys Ala Asp Lys Val Leu Gly Ile Glu Ser		
340	345	350
His His Asp Phe Leu Val Lys Val Lys Val Gly Lys Phe Met Ala Lys		
355	360	365
Leu Ala Glu His Met Phe Pro Lys Ser Gln Glu		
370	375	

<210> 5  
 <211> 1608  
 <212> DNA  
 <213> Homo sapiens

<400> 5  
 gtatcctggt gcatagactt aacactgtat ttttaactcag gtaatgtatg gcctttttgt 60  
 ttattttttt cctgcatttt tgggggggtgt tgaaataagt aaactgggaa ggtgcagggg 120  
 aattccttaaa ttcaatgcaa ggagtttttg ctgagtatct gcagcattca aggaattaat 180  
 attagtcact gagaacaaaa agcgaaatta gaaaatttca agtcacttct aggcctttag 240  
 gggagaagac gtgtagtgtat gaattctatc atttatgaag taccacttgg atccacaca 300  
 ctgtgcaaga ccttttagatc aggcgcctcc ctgggttttc ttcacctgt gcagcaggtg 360  
 ctgttatctc ctttttttaa ttattattta ttattattat tttttgagac aggatctccc 420  
 tttgtcactc aggcctggaat gcagaggcat gatcactgct cactgcagct tcgaccaccc 480  
 aggcctcaaag gagtctccca cctcgggtgc tgccacacct ggccaacttt tttgtatttt 540  
 tttggtagag accgggggtt caccatgttg cccaggctgg tcttgaactt ttggactcca 600  
 ggcactgtcc tgccctccgc tcacctagt ctgggattac agacatgagc cattgtgccc 660  
 gtccctgtgt ttccgtttta gctgaggagg aagggttaga taacttgccc agtcgggtgt 720  
 aggaccagca ctagtacagt gttgggcacg tagtaggtgt ttaatacatg accgatgagc 780  
 aaatggctcc agatgtctct ggttccatag gcagccttga atagggtttt acacacctga 840  
 tgagaatgac agcctgtgtt gactgagccc tgacttgtgt ccaaccctgc catagtgcc 900

gtgccttgca tgaattcaat aatttgagcc tagcagcaac cttagaggt aggtactgtt 960  
 acctccccgt ttataaatga gaagacaggg gcagtggaggc ccaagattga agagcttgtg 1020  
 gccaaagaaga tggagttgca ggtggtttgg ccatagagct gatgcttggc aaatgtgtta 1080  
 tatctgtgat ggtcatttta ggttaataaa agctctgttt ttagattgat aattctaagg 1140  
 gtttatcatc aagggtgatg agaaggtgag ggagccccctg tgtgtagcgc agcaactctg 1200  
 gccttctgga cagtaggtag gcatgtgac actgttgtca ctaaacctgg gaaatgatcc 1260  
 ctgggtcagg gttcattaat tgccaaatga ttaaagtaat aaagctgaca ctggaaactt 1320  
 atctaacttc atttcttttc cttgatttac aaagatagtc aatacathtt cctacaaaaa 1380  
 agaactggcc agccgtgggt gctcatgcct gtaatcctag cagtttagga agccgaggtg 1440  
 ggcggtatgc ttgaggtcag gagttcgaga ccagtctggc caacatggtt gaaatcctgt 1500  
 ctctactgaa aatacaaaaa ttatctgggc atagtggtgt gtgcctgtaa ttgcagcctg 1560  
 ggcaacggag tgagagactg tctcaggaaa aaaaaaaaaa aaaaaaaaaa 1608

<210> 6

<211> 122

<212> PRT

<213> Homo sapiens

<400> 6

Met Asn Ser Ile Ile Tyr Glu Val Pro Thr Gly Ser His Thr Leu Cys  
 1 5 10 15

Lys Thr Phe Arg Ser Gly Ala Ser Leu Gly Phe Leu His Pro Val Gln  
 20 25 30

Gln Val Leu Leu Phe Pro Phe Leu Asn Tyr Tyr Leu Leu Leu Leu Phe  
 35 40 45

Phe Glu Thr Gly Ser Pro Phe Val Thr Gln Ala Gly Met Gln Arg His  
 50 55 60

Asp His Cys Ser Leu Gln Leu Arg Pro Pro Arg Leu Lys Gly Val Ser  
 65 70 75 80

His Leu Gly Cys Cys His Thr Trp Pro Thr Phe Leu Tyr Phe Phe Gly  
 85 90 95

Arg Asp Arg Gly Phe Thr Met Leu Pro Arg Leu Val Leu Asn Phe Trp  
 100 105 110

Thr Pro Ala Ile Cys Leu Pro Pro Pro Pro  
 115 120

<210> 7

<211> 1969

<212> DNA

<213> Homo sapiens

<400> 7

ggaagtttgt ggctgcagct gccgtgggtt tctcctgggt tccagcagaa acggcggcgg 60  
 cgcaaggtgt ggctgggcca acccaggatc tcccaggacc ctccgtctct cgcgacaagg 120  
 ggcccgcgct tgccaaggcc gacgggcagg agtgaacgtg gctccgtgg gtctgcagcc 180  
 ccgataggcc aattgtacag aatttaaacc gtctctcaga tgtgtacagt agaactcaag 240  
 aagacagact accaagggtc atctgaagtc gtgattgggt cactaataac accaggacaa 300  
 agttaaggga tcactactca agcataagcc ccagttttca taagactgct gtgaagatgt 360  
 ttgatataaa ggcttgggct gagtatgttg tggaatgggc tgcaaaggac ccctatggct 420  
 tccttacaac cgttattttg gcccttactc cactgttctc agcaagtgtc gtactgtctt 480  
 ggaaattggc caagatgatt gaggccaggg agaaggagca aaagaagaag caaaaacgcc 540  
 aagaaaacat tgcaaaaagct aaacgactaa aaaaggattg aaggactgaa caggctttgc 600

```

aaccagagga aaatcatttg gaaaattaca cagcttttga agaatccact aaagtttctt 660
ctttggattt cttgacagta tgatttagta aatgaaatgt gaccaaatgg aagaatcatg 720
ttagttctga cctcaatact atagtaactt ttaggcgtgg gtgtagaagt ttatagggtt 780
ctattgacag ttattgtaaa ttagcattta ctgtggtaca aattctttat aactgactta 840
gtcatttgcc gcttagcagt ttatatactg aaatgaaaac atctgtggtg gaaaagtgc 900
tttagattat gaactcaatt caaatgaact ctatttaaaa tggggtccta ttttggacaa 960
aggaaattaa gaatgttaaa gtcagaacag tcttgaggta aaaagtgtgc tttggcttaa 1020
aagggataca gtatattaat tacatctttt attattattg tttatttctt agaatcattt 1080
ctggctttct caaaaacaaa taatattaat gagtacttct atttgcgtgc tttttcttat 1140
tacagccttt gagacagctg gtaattataa gtcattttcc attttttaaa acataatttt 1200
ataaagaatt ctcttatctc gactatgtag aataccacct actggacaga acaatttttg 1260
tactcacaaa cactgccatt ttcttagaga tggcttgaga ggagtaacac tatggtttaa 1320
agcttgagcgt aaaaatgcca aacactgtag taccttgga cccagtttat tctgtgtgta 1380
agcagaactg taaaatagtt aaaatgtctt atcaagtaat tcgccgatta caaagacacc 1440
atttgttttt tatttcattc ttgtttttaa ctcatgtggc agtgatattt aatactttct 1500
gatcaaacag gttcaaaagta aaacgttaaa tttcacattt cttttaaaga actcttaaag 1560
tgtaacagtt acgccatact tcataagtgg taaagaaagg tataaaattt ggaaacattt 1620
tggtgggcat agtagtgatt gggtgaaaag gataaattat atcaaaatga gaatgtgctg 1680
taattggaag tagggagcta aaggatgttt ctttcagttt agtagaactg gaacgtttta 1740
ctattaaaca tggcttttat aaatgcattg tccaataatt ttattcactg ttagtattta 1800
attcactgtc agcttattaa tgttttctgt acccattaat gaattttaaa ttacmaaaaa 1860
ttgtctwgca gctacagttt aaaaatgaaa ctagacatta aaataaattt gataattttt 1920
ttttaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1969

```

&lt;210&gt; 8

&lt;211&gt; 74

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

```

Met Phe Asp Ile Lys Ala Trp Ala Glu Tyr Val Val Glu Trp Ala Ala
  1             5             10            15

```

```

Lys Asp Pro Tyr Gly Phe Leu Thr Thr Val Ile Leu Ala Leu Thr Pro
      20             25             30

```

```

Leu Phe Leu Ala Ser Ala Val Leu Ser Trp Lys Leu Ala Lys Met Ile
      35             40             45

```

```

Glu Ala Arg Glu Lys Glu Gln Lys Lys Lys Gln Lys Arg Gln Glu Asn
      50             55             60

```

```

Ile Ala Lys Ala Lys Arg Leu Lys Lys Asp
      65             70

```

&lt;210&gt; 9

&lt;211&gt; 819

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

```

tgacttttta tatatatctc agaggcaaac attcctagtg aagggttggt ttctctcttg 60
accttgaggg ggtcttttca tctgctcagg caccttcgca tccccgtgga tcagggtc 120
gagcagagga gagtcagcag tctctaaatt atcatcatct cctacctgca catgtacaca 180
aaaaataagcc tgaatgcttt ttcttagtat gcaatttgct gtctattttt aacttgta 240
cagaggggcca aaaagaaaat tccatgagga catgagagtg cattgaggtt gcaggta 300
agtcaacaaa gaacctgaaa taattgccgg aatgatatcc tctaaaagat gtgagcctct 360
cagagagaga gagagagggg tctctctgca acaggcatcg tgtgtgtgtt ttatgtccct 420
tctctctctg tgctgtgcac ttaattcggt tccagccgtg tcagggagac tcgagaaaaa 480

```

```

aatccccacca ttaaagacat gctctttgtt ttttcaatct gtgaccccag caatctcttt 540
agcaagccat ggttcagtga actggcacac agcagccggt cggcagtgga aaaaatcata 600
aaacagatgg aagctttaca tttttgttta gtttttaaga gcagttttta taacatcgct 660
taagaccatt ctgatgcac atactgttta cactcaaagc tttgtagcta agatgtttac 720
agtatggaga atgttttaag atattttata gttttgatat ttagataatt ggcaaaaaaa 780
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 819

```

<210> 10  
 <211> 89  
 <212> PRT  
 <213> Homo sapiens

<400> 10  
 Met Ile Ser Ser Lys Arg Cys Glu Pro Leu Arg Glu Arg Glu Arg Gly  
 1 5 10 15  
 Phe Leu Leu Gln Gln Ala Ser Cys Val Cys Phe Met Ser Leu Leu Phe  
 20 25 30  
 Cys Cys Cys Ala Leu Asn Ser Val Pro Ala Val Ser Gly Arg Leu Glu  
 35 40 45  
 Lys Lys Ile Pro Pro Leu Lys Thr Cys Ser Leu Phe Phe Gln Ser Val  
 50 55 60  
 Thr Pro Ala Ile Ser Leu Ala Ser His Gly Ser Val Asn Trp His Thr  
 65 70 75 80  
 Ala Ala Val Arg Gln Trp Lys Lys Ser  
 85

<210> 11  
 <211> 1969  
 <212> DNA  
 <213> Homo sapiens

<400> 11  
 acactccatc tcccgggagc aaggggaaac tccgagagga gggcaacaga gccagcatct 60  
 tgccagggcc cgggaggagg ggttccccgc tacgcctgtg ccggaggagt tccagtcacc 120  
 gagcgagggg cgcaagggtg ggtgcacect gcgctgcggc gggcgcgcta cccagacgct 180  
 ggtgtgcaga gccacatgaa gcctgctggg gactgggggc caggagagcag caagccagct 240  
 gggactgagg cggacgctgt ctccaggaga cgctgactcg caaagacact cccttccttg 300  
 tgccctgggt aaaaagtctc tcctgggggc cctggccatc ctgaatatcc agaattggtg 360  
 ttctgaagtt cttctgcatg agttttctct gccacctgtg tcaaggctac ttcgatggcc 420  
 ccctctaccc agagatgtcc aatgggactc tgcaccacta cttcgtgccc gatggggact 480  
 atgaggagaa cgatgacccc gagaagtgcc agctgctctt cagggtgagt gaccacaggc 540  
 gctgctccca gggggagggg agccagggtg gcagcctgct gagectcacc ctgcgggagg 600  
 agttcacctg gctgggcccgc cagggtggagg atgctgggcg cgtgctggag ggcacagca 660  
 aaagcatctc ctacgaccta gacggggaag agagctatgg caagtacctg cggcgggagt 720  
 cccaccagat cggggatgcc tactccaact cggacaaatc cctcactgag ctggagagca 780  
 agttcaagca gggccaggaa caggacagcc ggccaggagag caggctcaac gaggactttc 840  
 tgggaatgct ggtccacacc aggtccctgc tgaaggagac actggacatc tctgtggggc 900  
 tcagggacaa atacgagctg ctggccctca ccattaggag ccattgggacc cgactaggtc 960  
 ggctgaaaaa tgattatctt aaagtatagg tggaaggata caaatgctag aaagagggaa 1020  
 tcaaatcagc cccgttttgg aggggtgggg acagaagatg gggctacatt tccccatac 1080  
 ctactatttt tttatatccc gatttgcact ttgagaatac atctaaggtc atctttcaaa 1140  
 agagaaaaat tggacacttg agtgactttg tttttagttt tgtttttgta cattatttat 1200  
 gtgattgtta tggaattgtc acctggaaag aacaatttta agcaatgtca tttctagatg 1260  
 ggttttctaat tctgcagaga cacccgtttc agccacatct aaaagagcac agtttatgtg 1320

```

gtgcggaatt aaacttcccc atcctgcaga ttatgtggaa ataccctaaag ataatagtgc 1380
atagctcctt tcagcctcta gccttcactc ctgggctcca aaagctatcc cagttgcctg 1440
tttttcaaat gaggttcaag gtgctgcttt gcatgcctgc caaccatgg aagttgtttc 1500
ttacttcttt tctctcttat ttattaacca tggctctgaga gttgtttttg ttctatgtaa 1560
cagtattgcc acaaaactat aggcaaatcg tgtttgcagg gagatttctg atgcctctgt 1620
gggtgtgtgt aagttaaagt ggccacattt aagaaggcca agctttgtag tggttgcaca 1680
gtcacactga tatgctgatt tgcctcttct cattgtatgt ctatgctttg tcatcagtgc 1740
tatagtaa atacaaagaaa taggtagatt gtatgaacat acccacaat gcctatgatt 1800
taggttacca atgtattctt tctcatttgg ggttttgctt ctgtctgtct gtttattgga 1860
aacttgtagt tcaagtaggg ggaatcctaa ttctaataac tccttagcta agttttatta 1920
ttcaggcaat aaacatgttt tcatgtaaaa aaaaaaaaaa aaaaaaaaaa 1969

```

&lt;210&gt; 12

&lt;211&gt; 211

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

```

Met Val Phe Leu Lys Phe Phe Cys Met Ser Phe Phe Cys His Leu Cys
  1              5              10              15

```

```

Gln Gly Tyr Phe Asp Gly Pro Leu Tyr Pro Glu Met Ser Asn Gly Thr
      20              25              30

```

```

Leu His His Tyr Phe Val Pro Asp Gly Asp Tyr Glu Glu Asn Asp Asp
      35              40              45

```

```

Pro Glu Lys Cys Gln Leu Leu Phe Arg Val Ser Asp His Arg Arg Cys
      50              55              60

```

```

Ser Gln Gly Glu Gly Ser Gln Val Gly Ser Leu Leu Ser Leu Thr Leu
      65              70              75              80

```

```

Arg Glu Glu Phe Thr Val Leu Gly Arg Gln Val Glu Asp Ala Gly Arg
      85              90              95

```

```

Val Leu Glu Gly Ile Ser Lys Ser Ile Ser Tyr Asp Leu Asp Gly Glu
      100             105             110

```

```

Glu Ser Tyr Gly Lys Tyr Leu Arg Arg Glu Ser His Gln Ile Gly Asp
      115             120             125

```

```

Ala Tyr Ser Asn Ser Asp Lys Ser Leu Thr Glu Leu Glu Ser Lys Phe
      130             135             140

```

```

Lys Gln Gly Gln Glu Gln Asp Ser Arg Gln Glu Ser Arg Leu Asn Glu
      145             150             155             160

```

```

Asp Phe Leu Gly Met Leu Val His Thr Arg Ser Leu Leu Lys Glu Thr
      165             170             175

```

```

Leu Asp Ile Ser Val Gly Leu Arg Asp Lys Tyr Glu Leu Leu Ala Leu
      180             185             190

```

```

Thr Ile Arg Ser His Gly Thr Arg Leu Gly Arg Leu Lys Asn Asp Tyr
      195             200             205

```

```

Leu Lys Val
      210

```

<210> 13  
 <211> 2020  
 <212> DNA  
 <213> Homo sapiens

<400> 13  
 ggccgggaggg gcagtcggcc gcgggggcgga gcgcgcgatgc gccttctctgg gacccacggc 60  
 aggcgcgaat cccaacggcc ggccggcgcc ggggatactt ctacatagac ataatcaagt 120  
 tttgactatt tggaaaccaa gcatcattaa aattctctca aactcctaata tgcgaagaat 180  
 ccataacatt tcaagaagtgc ataacatttc tctgaacaag aaaagaagtgc attgaccacg 240  
 ttttaaaagt actctggcac tgggtgctgtg ttttcttccc ctccctaataa ttgaagaact 300  
 atggagaaat ggtacttgat gacagtagtg gttttaatag gactaacagt acgatggaca 360  
 gtgtctctta attcttattc aggtgctggt aaaccgccta tgtttgggtga ttatgaagct 420  
 cagagacact ggcaagaaat aacttttaat ttaccggtca aacaatggta ttttaacagc 480  
 agtgataaca atttacagta ttggggattg gattacccac ctcttacagc ttatcatagt 540  
 ctcttatgtg catatgtggc aaagtttata aatccagact ggattgctct ccatacatca 600  
 cgtgggatag agagtcaggc acataagctc ttcattgcgt caacagtttt aattgctgat 660  
 ctgctgattt acatacctgc agtggttttg tactgttggt gcttaaaaga aatctcaact 720  
 aagaaaaaga ttgctaattgc attatgcctc ttgctgtatc caggccttat tcttatagac 780  
 tatggacatt ttcaatataa ttctgtgagt cttggctttg ctttgtgggg tggtcttgga 840  
 atatcttgtg actgcgacct cctaggggtca ctggcatttt gcttagctat aaattataaa 900  
 cagatggaac ttaccacgc cttgccattt ttttgccttt tacttggcaa gtgttttaaa 960  
 aaaggcctca aaggaaaggg gtttgtgtkg ctagttaagc tagctkgtat tgttgtggct 1020  
 tcttctgttc tctgctggct gccattcttt acagaaaggg aacaaacct gcaggttcta 1080  
 agaagactct tcccggttga tctgtgatta tttgaggata aagtagccaa tatttgggtgc 1140  
 agcttcaatg tcttcttgaa gattaaggat attttgcac gtcacatcca attaataatg 1200  
 agcttttgtt ttacgttttt gagcctgctt cctgcattgca taaaattaat acttcagccc 1260  
 tcttccaaag gattcaaat ttacactggtt agctgtgcgc tatcattctt tttattttct 1320  
 ttccaagtac atgaaaaatc cattctcttg gtgtcactac cagtctgctt agttttaagt 1380  
 gaaattcctt ttatgtctac ttgggttttta cttgtgtcaa catttagtat gctacctctt 1440  
 ctattgaagg atgaactcct aatgcctctt gttgtgacaa caatggcatt ttttatagct 1500  
 tgtgtaactt ccttttcaat atttgaaaag acttctgaag aagaactgca gttgaaatcc 1560  
 ttttccattt ctgtgaggaa atatcttcca tgtttwacat ttctttccag aattawacaa 1620  
 tatttgttct ttatctcagt catcactatg gtgcttctga cgttgatgac tgtcacactg 1680  
 gatcctcctc agaaactacc ggacttggtt tctgtattgg tgtgtttkgt atcttgcttg 1740  
 aacttcctgt tcttcttggt atactttaac attattatta tgtgggattc caaaagtgga 1800  
 agaaatcaga agaaaatcag ctagctgtat tcttaacaa attgtttcct aaacaaatgt 1860  
 gaaaatgtga acagtgtga aagggtttgt gaacttttgc ctatgtataa atgaaattac 1920  
 cattttgaga accatggaac cacaggaaag gaaatggtga aaagtcattg ttgtctacac 1980  
 maaataaatg tatatggaga ccaaaaaaaaa aaaaaaaaaa 2020

<210> 14  
 <211> 507  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> UNSURE  
 <222> (230)

<220>  
 <221> UNSURE  
 <222> (236)

<220>  
 <221> UNSURE  
 <222> (432)

<220>

&lt;221&gt; UNSURE

&lt;222&gt; (439)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (476)

&lt;400&gt; 14

Met Glu Lys Trp Tyr Leu Met Thr Val Val Val Leu Ile Gly Leu Thr  
 1 5 10 15

Val Arg Trp Thr Val Ser Leu Asn Ser Tyr Ser Gly Ala Gly Lys Pro  
 20 25 30

Pro Met Phe Gly Asp Tyr Glu Ala Gln Arg His Trp Gln Glu Ile Thr  
 35 40 45

Phe Asn Leu Pro Val Lys Gln Trp Tyr Phe Asn Ser Ser Asp Asn Asn  
 50 55 60

Leu Gln Tyr Trp Gly Leu Asp Tyr Pro Pro Leu Thr Ala Tyr His Ser  
 65 70 75 80

Leu Leu Cys Ala Tyr Val Ala Lys Phe Ile Asn Pro Asp Trp Ile Ala  
 85 90 95

Leu His Thr Ser Arg Gly Tyr Glu Ser Gln Ala His Lys Leu Phe Met  
 100 105 110

Arg Thr Thr Val Leu Ile Ala Asp Leu Leu Ile Tyr Ile Pro Ala Val  
 115 120 125

Val Leu Tyr Cys Cys Cys Leu Lys Glu Ile Ser Thr Lys Lys Lys Ile  
 130 135 140

Ala Asn Ala Leu Cys Ile Leu Leu Tyr Pro Gly Leu Ile Leu Ile Asp  
 145 150 155 160

Tyr Gly His Phe Gln Tyr Asn Ser Val Ser Leu Gly Phe Ala Leu Trp  
 165 170 175

Gly Val Leu Gly Ile Ser Cys Asp Cys Asp Leu Leu Gly Ser Leu Ala  
 180 185 190

Phe Cys Leu Ala Ile Asn Tyr Lys Gln Met Glu Leu Tyr His Ala Leu  
 195 200 205

Pro Phe Phe Cys Phe Leu Leu Gly Lys Cys Phe Lys Lys Gly Leu Lys  
 210 215 220

Gly Lys Gly Phe Val Xaa Leu Val Lys Leu Ala Xaa Ile Val Val Ala  
 225 230 235 240

Ser Phe Val Leu Cys Trp Leu Pro Phe Phe Thr Glu Arg Glu Gln Thr  
 245 250 255

Leu Gln Val Leu Arg Arg Leu Phe Pro Val Asp Arg Gly Leu Phe Glu  
 260 265 270

Asp Lys Val Ala Asn Ile Trp Cys Ser Phe Asn Val Phe Leu Lys Ile

275                      280                      285  
 Lys Asp Ile Leu Pro Arg His Ile Gln Leu Ile Met Ser Phe Cys Phe  
 290                      295                      300  
 Thr Phe Leu Ser Leu Leu Pro Ala Cys Ile Lys Leu Ile Leu Gln Pro  
 305                      310                      315                      320  
 Ser Ser Lys Gly Phe Lys Phe Thr Leu Val Ser Cys Ala Leu Ser Phe  
 325                      330                      335  
 Phe Leu Phe Ser Phe Gln Val His Glu Lys Ser Ile Leu Leu Val Ser  
 340                      345                      350  
 Leu Pro Val Cys Leu Val Leu Ser Glu Ile Pro Phe Met Ser Thr Trp  
 355                      360                      365  
 Phe Leu Leu Val Ser Thr Phe Ser Met Leu Pro Leu Leu Leu Lys Asp  
 370                      375                      380  
 Glu Leu Leu Met Pro Ser Val Val Thr Thr Met Ala Phe Phe Ile Ala  
 385                      390                      395                      400  
 Cys Val Thr Ser Phe Ser Ile Phe Glu Lys Thr Ser Glu Glu Glu Leu  
 405                      410                      415  
 Gln Leu Lys Ser Phe Ser Ile Ser Val Arg Lys Tyr Leu Pro Cys Xaa  
 420                      425                      430  
 Thr Phe Leu Ser Arg Ile Xaa Gln Tyr Leu Phe Leu Ile Ser Val Ile  
 435                      440                      445  
 Thr Met Val Leu Leu Thr Leu Met Thr Val Thr Leu Asp Pro Pro Gln  
 450                      455                      460  
 Lys Leu Pro Asp Leu Phe Ser Val Leu Val Cys Xaa Val Ser Cys Leu  
 465                      470                      475                      480  
 Asn Phe Leu Phe Phe Leu Val Tyr Phe Asn Ile Ile Ile Met Trp Asp  
 485                      490                      495  
 Ser Lys Ser Gly Arg Asn Gln Lys Lys Ile Ser  
 500                      505

&lt;210&gt; 15

&lt;211&gt; 940

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

gtttggaggt gcttgccctta gagcaaggga aacagctctc attcaaagga actagaagcc 60  
 tctccctcag tggtagggag acagccagga gcggttttct gggaactgtg ggatgtgccc 120  
 ttgggggccc gagaaaacag aaggaagatg ctccagacca gtaactacag cctggtgctc 180  
 tctctgcagt tcctgctgct gtcctatgac ctctttgtca attccttctc agaactgctc 240  
 caaaagactc ctgtcatcca gcttggtgctc ttcacatcc aggatattgc agtcctcttc 300  
 aacatcatca tcatttttct catgttcttc aacaccttcg tcttccaggc tggcctggtc 360  
 aacctctat tccataagtt caaagggacc atcatcctga cagctgtgta ctttgccctc 420  
 agcatctccc ttcatgtctg ggtcatgaac ttacgctgga aaaactocaa cagcttcata 480  
 tggacagatg gacttcaaatt gctgtttgta ttccagagac tagtttggac cgaattctaa 540

```

tttttcttga ctacaagtct tcaaaataat gttttcattt tttttctctt ttttccattt 600
ttttccaatt tggagtcact gaaaactaag ctgtgctttc ataaagccct gcaaactgaa 660
tctagacaac ttcagaagaa aaataacagc aacctattta catacataag ccactttcat 720
acctgcctac cgatgtatgg acttcagagt aatgtggctt atagcaattt tccaggattg 780
ttcttttgct tgttgttggt ctcccttccct cccctattt tgtctttatg ggacatgaca 840
cttcacaacc ttctaaaaat gaggtttccct aataactcag gacctactcg tctagaaata 900
aaccatccta gccatgagag ataagataaa aaaaaaaaaa 940

```

&lt;210&gt; 16

&lt;211&gt; 130

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

```

Met Leu Gln Thr Ser Asn Tyr Ser Leu Val Leu Ser Leu Gln Phe Leu
  1              5              10              15

```

```

Leu Leu Ser Tyr Asp Leu Phe Val Asn Ser Phe Ser Glu Leu Leu Gln
      20              25              30

```

```

Lys Thr Pro Val Ile Gln Leu Val Leu Phe Ile Ile Gln Asp Ile Ala
      35              40              45

```

```

Val Leu Phe Asn Ile Ile Ile Ile Phe Leu Met Phe Phe Asn Thr Phe
      50              55              60

```

```

Val Phe Gln Ala Gly Leu Val Asn Leu Leu Phe His Lys Phe Lys Gly
      65              70              75              80

```

```

Thr Ile Ile Leu Thr Ala Val Tyr Phe Ala Leu Ser Ile Ser Leu His
      85              90              95

```

```

Val Trp Val Met Asn Leu Arg Trp Lys Asn Ser Asn Ser Phe Ile Trp
      100             105             110

```

```

Thr Asp Gly Leu Gln Met Leu Phe Val Phe Gln Arg Leu Val Trp Thr
      115             120             125

```

```

Glu Phe
      130

```

&lt;210&gt; 17

&lt;211&gt; 1348

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 17

```

gctgcttgca ggaattcaac atcatggaaa agaataaaagg atgggctctc ctgggaggaa 60
aagatggcca tcttcaggga ctatttctcc ttgccaacgc attgctggaa agaaatcagc 120
tccttgacac gaaggtoatg tacttattag tccctctctc taaccgaggg aatgataaac 180
ataaactcac atctgcaggc ttttttgttg agcttctccg gagtccagtg gccaagagac 240
tgcccagcat atactctgtt gcccgcttta aagactggct acaagatgga aatcatctct 300
ttagaattct cggcctgagg ggactgtaca atcttgttgg acaccaggag atgagagaag 360
acatcaagag cctgttgcca tacattgtag acagcttgcg tgaaaccgat gagaagatcg 420
ttctgtcagc catccagata ctctcgcaac ttgttagaac aatggatttc actaccctgg 480
ctgccatgat gaggaccctg ttctccttat ttggtgatgt gagatctgat gttcatcggt 540
tctcctgtac tctcttttga gccgccataa agtctgtaaa aaaccagat aagaagagta 600
tagagaacca agtcctggac agcttggtcc cactacttct gtattctcag gatgaaaatg 660
atgcagtagc tgaggagagc aggcaagtcc taactatatg tgcccagttc ctgaagtgga 720

```

```

agctgccccca agaagtgtac tccaaagatc cctggcacat caaacctact gaagcaggaa 780
caatctgcag attctttgaa aaaaagtgcaggggaaaat taacatccta gaacaaacac 840
tgatgtactc caagaaccca aaacttccca tcagaagatc agcagtcttg tttgtaggcc 900
ttttatcgaa gtacatggat cacaatgagc tcaggaggat ggggtactgac tggatagagg 960
acgatctgag agacctgctg tgtgacctg agccctcgtc gtgcacatc gcttcccaga 1020
ctctgttact agtccagatg gcgagggccg aacccaaaacc taagcagaga gtgaactggc 1080
tgcagaagct catgggcagg tcctctgcct agaaacacaa ggcaagcaac atcagagaca 1140
gaatcttgct atgttgctgc gcaagctagt cttgaactca tggcctcaag tcactctcct 1200
gtgtcagcct cccaaagtgc tgggattaca agcatgcacc acggcaccca gcagaattcc 1260
agtcttgaga aacaggtcaa ggacagcttc aaaagagatt ctaaataaat gttaatgtta 1320
caatgttaaa aaaaaaaaaa aaaaaaaaaa 1348

```

&lt;210&gt; 18

&lt;211&gt; 362

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 18

```

Met Glu Lys Asn Lys Gly Trp Ala Leu Leu Gly Gly Lys Asp Gly His
  1             5             10             15

```

```

Leu Gln Gly Leu Phe Leu Leu Ala Asn Ala Leu Leu Glu Arg Asn Gln
      20             25             30

```

```

Leu Leu Ala Gln Lys Val Met Tyr Leu Leu Val Pro Leu Leu Asn Arg
      35             40             45

```

```

Gly Asn Asp Lys His Lys Leu Thr Ser Ala Gly Phe Phe Val Glu Leu
      50             55             60

```

```

Leu Arg Ser Pro Val Ala Lys Arg Leu Pro Ser Ile Tyr Ser Val Ala
      65             70             75             80

```

```

Arg Phe Lys Asp Trp Leu Gln Asp Gly Asn His Leu Phe Arg Ile Leu
      85             90             95

```

```

Gly Leu Arg Gly Leu Tyr Asn Leu Val Gly His Gln Glu Met Arg Glu
      100            105            110

```

```

Asp Ile Lys Ser Leu Leu Pro Tyr Ile Val Asp Ser Leu Arg Glu Thr
      115            120            125

```

```

Asp Glu Lys Ile Val Leu Ser Ala Ile Gln Ile Leu Leu Gln Leu Val
      130            135            140

```

```

Arg Thr Met Asp Phe Thr Thr Leu Ala Ala Met Met Arg Thr Leu Phe
      145            150            155            160

```

```

Ser Leu Phe Gly Asp Val Arg Ser Asp Val His Arg Phe Ser Val Thr
      165            170            175

```

```

Leu Phe Gly Ala Ala Ile Lys Ser Val Lys Asn Pro Asp Lys Lys Ser
      180            185            190

```

```

Ile Glu Asn Gln Val Leu Asp Ser Leu Val Pro Leu Leu Leu Tyr Ser
      195            200            205

```

```

Gln Asp Glu Asn Asp Ala Val Ala Glu Glu Ser Arg Gln Val Leu Thr
      210            215            220

```

Ile Cys Ala Gln Phe Leu Lys Trp Lys Leu Pro Gln Glu Val Tyr Ser  
225 230 235 240

Lys Asp Pro Trp His Ile Lys Pro Thr Glu Ala Gly Thr Ile Cys Arg  
245 250 255

Phe Phe Glu Lys Lys Cys Lys Gly Lys Ile Asn Ile Leu Glu Gln Thr  
260 265 270

Leu Met Tyr Ser Lys Asn Pro Lys Leu Pro Ile Arg Arg Ser Ala Val  
275 280 285

Leu Phe Val Gly Leu Leu Ser Lys Tyr Met Asp His Asn Glu Leu Arg  
290 295 300

Arg Met Gly Thr Asp Trp Ile Glu Asp Asp Leu Arg Asp Leu Leu Cys  
305 310 315 320

Asp Pro Glu Pro Ser Leu Cys Ile Ile Ala Ser Gln Thr Leu Leu Leu  
325 330 335

Val Gln Met Ala Arg Ala Glu Pro Lys Pro Lys Gln Arg Val Asn Trp  
340 345 350

Leu Gln Lys Leu Met Gly Arg Ser Ser Ala  
355 360

<210> 19

<211> 1656

<212> DNA

<213> Homo sapiens

<400> 19

```

cttctcccac cctcgcctgc gtagccatgg cggagccgtc ggcgggccact cagtcccatt 60
ccatctcctc gtcgtccttc ggagccgagc cgtccgcgcc cggcgggcgc gggagcccag 120
gagcctgccc cgccttgggg acgaagagct gcagctcctc ctgtgcggtg cagcatctga 180
ttttctggag agatgtgaag aagactgggt ttgtctttgg caccacgctg atcatgctgc 240
tttccctggc agctttcagt gtcacagtg tggttcttta cctcatcctg gctcttctct 300
ctgtcaccat cagcttcagg atctacaagt ccgtcatcca agctgtacag aagtcagaag 360
aaggccatcc attcaaagcc tacctggaag tagacattac tctgtcctca gaagctttcc 420
ataattacat gaatgctgcc atggtgcaca tcaacagggc cctgaaactc attattcgtc 480
tctttctggg agaagatctg gttgactcct tgaagctggc tgtcttcatg tggctgatga 540
cctatgttgg tgcgtgtttt aacggaatca ccttctaat tcttgcgtga ctgctcattt 600
tcagtgtccc gattgtctat gagaagtaca agaccagat tgatcactat gttggcatcg 660
cccagatca gaccaagtca attgttgaag agatccaagc aaaactccct ggaatcgcca 720
aaaaaaaggc agaataagta catggaaacc agaaatgcaa cagttactaa aacaccattt 780
aatagttata acgtcgttac ttgtactatg aaggaaaata ctcagtgtca gcttgagcct 840
gcattccaag cttttttttt taatttggtg tttctccca tcttttcctt ttaaccctca 900
gtatcaagca caaaaattga tggactgata aaagaactat cttagaactc agaagaagaa 960
agaatcaaat tcataggata agtcaatacc ttaatgggtg tagagccttt acctgtagct 1020
tgaaagggga aagattggag gtaagagaga aaatgaaaga acacctctgg gtccctctgt 1080
ccagttttca gcaactagct tactcagcta tccattatag ttttgccctt aagaagtcac 1140
gattaactta tgaaaaaatt atttggggac aggagtgtga taccttccct ggtttttttt 1200
tgcagccctc aaatcctatc ttcctgcccc acaatgtgag cagctacccc tgatactcct 1260
tttctttaat gatttaacta tcaacttgat aaataactta taggtgatag tgataattcc 1320
tgattccaag aatgccatct gataaaaaag aatagaaatg gaaagtggga ctgagaggga 1380
gtcagcaggc atgctgcggt ggcggtcact ccctctgcca ctatccccag ggaaggaaag 1440
gtcccgccat ttgggaaagt ggtttctacg tcaactggaca ccggttctga gcattagttt 1500
gagaactcgt tcccgaatgt gctttcctcc ctctccctcg cccacctcaa gtttaataaa 1560

```

taaggttgta cttttcttac tataaaataa atgtctgtaa ctgcaaaaaa aaaaaaaaaa 1620  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 1656

<210> 20  
 <211> 236  
 <212> PRT  
 <213> Homo sapiens

<400> 20  
 Met Ala Glu Pro Ser Ala Ala Thr Gln Ser His Ser Ile Ser Ser Ser  
 1 5 10 15  
 Ser Phe Gly Ala Glu Pro Ser Ala Pro Gly Gly Gly Gly Ser Pro Gly  
 20 25 30  
 Ala Cys Pro Ala Leu Gly Thr Lys Ser Cys Ser Ser Ser Cys Ala Val  
 35 40 45  
 His Asp Leu Ile Phe Trp Arg Asp Val Lys Lys Thr Gly Phe Val Phe  
 50 55 60  
 Gly Thr Thr Leu Ile Met Leu Leu Ser Leu Ala Ala Phe Ser Val Ile  
 65 70 75 80  
 Ser Val Val Ser Tyr Leu Ile Leu Ala Leu Leu Ser Val Thr Ile Ser  
 85 90 95  
 Phe Arg Ile Tyr Lys Ser Val Ile Gln Ala Val Gln Lys Ser Glu Glu  
 100 105 110  
 Gly His Pro Phe Lys Ala Tyr Leu Asp Val Asp Ile Thr Leu Ser Ser  
 115 120 125  
 Glu Ala Phe His Asn Tyr Met Asn Ala Ala Met Val His Ile Asn Arg  
 130 135 140  
 Ala Leu Lys Leu Ile Ile Arg Leu Phe Leu Val Glu Asp Leu Val Asp  
 145 150 155 160  
 Ser Leu Lys Leu Ala Val Phe Met Trp Leu Met Thr Tyr Val Gly Ala  
 165 170 175  
 Val Phe Asn Gly Ile Thr Leu Leu Ile Leu Ala Glu Leu Leu Ile Phe  
 180 185 190  
 Ser Val Pro Ile Val Tyr Glu Lys Tyr Lys Thr Gln Ile Asp His Tyr  
 195 200 205  
 Val Gly Ile Ala Arg Asp Gln Thr Lys Ser Ile Val Glu Lys Ile Gln  
 210 215 220  
 Ala Lys Leu Pro Gly Ile Ala Lys Lys Lys Ala Glu  
 225 230 235

<210> 21  
 <211> 29  
 <212> DNA  
 <213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 21  
antgacttca gttgagggca agtctctgg 29

<210> 22  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 22  
tncagaaaga ctgcagggat tggggacaa 29

<210> 23  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 23  
antcatcact acacgtcttc tccctaca 29

<210> 24  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 24  
gnctgagtat gttgtggaat gggctgcaa 29

<210> 25

<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 25  
tngtgactgt atacctgcaa cctcaatgc 29

<210> 26  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 26  
tngccttgac acaggtggca gaagaaact 29

<210> 27  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 27  
cngactggta gtgacaccaa gagaatgga 29

<210> 28  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 28  
anagcacagc ttagttttca gtgactcca 29

<210> 29  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 29  
gcataactc tgttgccgc 20

<210> 30  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<400> 30  
ctgccactat ccccagg 18

<210> 31  
<211> 29  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (2)  
<223> biotinylated phosphoramidite residue

<400> 31  
antggtgtgc cactcccaac aatctttcc 29

<210> 32  
<211> 2505  
<212> DNA  
<213> Homo sapiens

<400> 32  
ccagctcccc actgccctga gggcgggcgg gcctgcggcg gagggaaaaa ggaagaggag 60  
aaggaaattg tcccgaatcc ctgcaggcca gtacctggaa gattccataa agtcgggggtg 120  
cttgagggcg tagggccgag accgtcgcg gtactgaggc gcctccgtcg tctctccac 180  
tcgcccggcg ctttccaaga catatgtccc gcttcgagcc catttcgatg ctgcgaaacg 240  
gtgagctgcg ggggtgtttg ggaagagctc agagactggg aaatgggaat ctgctgggag 300  
cctagggcgg caatccggaa agggagctgt ggctgggtg ttggccccta gtccaccagg 360  
acagtgcggg aggggaatgg ctggatatgg gggcggggt ggtgagatgc aacgcgatat 420  
gtcagcagaa ccccaagaga ggtaatagg gtgggaaacc tctgacaacc aggcctccga 480  
attagaaaag agttttgtgt tctggggact agtccgtcca ccaagcgctc agtggcggca 540  
gtttcccgctc tttctgctg tggctgtgtc ttactgacca tggctctgtg tctagtgggt 600  
ccaagcctct cccgggtggc cagtctttct gtaggttgcg gcacaacgcc agggaaaaga 660  
agaggaagga atttaactct aatcggtgga ggtcgatttg agggctctgct gtagcagggtg 720  
gtcccgcttg aagcgaggga ggaagtttcc tccgatcagt agagattgga aagattgttg 780

```

ggagtggcac accactaggg aaaagaagaa ggggcgaact gcttgtcttg aggaggtcaa 840
ccccagaat cagctcttgt ggccctgaag tggctgaaga cgatcacccct ccacaggctt 900
gagcccagtc ccacagcctt cctccccag cctgagtga cactctattc cttgggtccct 960
gctattgtcg gggacgattg catgggctac gccaggaaa taggctgggt gaccgcaggc 1020
ctggtgattg gggctggcgc ctgctattgc atttatagac tgactagggg aagaaaacag 1080
aacaaggaaa aaatggctga ggggtgatct ggggatgtgg atgatgctgg ggactgttct 1140
ggggccaggt ataatgactg gtctgatgat gatgatgaca gcaatgagag caagagtata 1200
gtatggtacc caccttgggc toggattggg actgaaactg gaaccagagc tagggccagg 1260
gcaagggccca gggctacccg ggcacgtcgg gctgtccaga aacgggcttc ccccaattca 1320
gatgataccg ttttgtcccc tcaagagcta caaaaggctt tttgcttggg tgagatgtct 1380
gaaaagcctt atattcttga agcagcttta attgctctgg gtaacaatgc tgcttatgca 1440
tttaacagag atattattcg tgatctgggt ggtctcccaa ttgtcgcaa gattctcaat 1500
actcgggac ccatagttaa ggaaaaggct ttaattgtcc tgaataactt gagtgtgaat 1560
gctgaaaatc agcgcaggct taaagtatac atgaatcaag tgtgtgatga cacaatcact 1620
tctcgcttga actcatctgt gcagcttgct ggactgagat tgcttacaaa tatgactgtt 1680
actaatgagt atcagcacat gcttgcta at tccatttctg actttttctg tttattttca 1740
gcgggaaatg aagaaaccaa acttcagggt ctgaaactcc tttgaattt ggctgaaaat 1800
ccagccatga ctagggaact gctcagggcc caagtaccat cttcactggg ctccctcttt 1860
aataagaagg agaacaaaga agttattctt aaacttctgg tcatatttga gaacataaat 1920
gataatttca aatgggaaga aaatgaacct actcagaatc aattcgggtga aggttcactt 1980
ttttctttt taaaagaatt tcaagtgtgt gctgataagg ttctgggaat agaaagtcac 2040
catgattttt tggtgaaagt aaaagttgga aaattcatgg ccaaacttgc tgaacatatg 2100
ttcccaaaga gccaggaata acaccttgat tttgtaattt agaagcaaca cacattgtaa 2160
actattcatt ttctccacct tgtttatatg gtaaaggaa cctttcagct gccagttttg 2220
aataatgaat atcatattgt atcatcaatg ctgatattta actgagttgg tcttttaggtt 2280
taagatggat aaatgaatat cactacttgt tctgaaaaca tgtttgttgc tttttatctc 2340
gctgcctaga ttgaaatatt ttgctatttc ttctgcataa gtgacagtga accaattcat 2400
catgagtaag ctcccttctg tcattttcat tgatttaatt tgtgtatcat caataaaatt 2460
gtatgttaat gctggaaaga aaaaaaaaa aaaaaaaaa aaaaaa 2505

```

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/25149

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 252.3, 320.1, 91.1, 91.2; 536/23.1, 23.5, 24.31; 530/350; 514/12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
none

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Dialog and APS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Database EMBL/GenBank, Isolation and Characterization of a cDNA Encoding a Synaptonemal Complex Protein. Accessions A56822; S20742. Biochem. Cell Biol., 1992, Vol. 70, pages 1030-1038, Chen et al. 10-September-1997, see entire document.	1-15
Y	CHEN et al. Isolation and Characterization of a cDNA Encoding a Synaptonemal Complex Protein. Biochem. Cell Biol. (1992) Vol. 70, pages 1030-1038, see entire document.	1-15



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

01 FEBRUARY 1999

Date of mailing of the international search report

08 MAR 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231Authorized officer  
ENRIQUE D. LONGTON

Facsimile No. (703) 305-3730

Telephone No. (703) 305-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/25149

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-15

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/25149

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07H 21/04, 21/02; C12N 15/11, 15/00, 1/21, 15/63; C07K 14/00; A61K 38/00; C12P 19/34

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/69.1, 252.3, 320.1, 91.1, 91.2; 536/23.1, 23.5, 24.31; 530/350; 514/12

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

- Group I, claim(s) 1-15, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:1 and 2 as well as processes for producing the polynucleotides and polypeptides.
- Group II, claim(s) 16-17, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:32 and 4 as well as processes for producing the polynucleotides and polypeptides.
- Group III, claim(s) 18-20, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:5 and 6 as well as processes for producing the polynucleotides and polypeptides.
- Group IV, claim(s) 21-23, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:7 and 8 as well as processes for producing the polynucleotides and polypeptides.
- Group V, claim(s) 24-26, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:9 and 10 as well as processes for producing the polynucleotides and polypeptides.
- Group VI, claim(s) 27-29, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:11 and 12 as well as processes for producing the polynucleotides and polypeptides.
- Group VII, claim(s) 30-32, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:13 and 14 as well as processes for producing the polynucleotides and polypeptides.
- Group VIII, claim(s) 33-35, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:15 and 16 as well as processes for producing the polynucleotides and polypeptides.
- Group IX, claim(s) 36-38, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:17 and 18 as well as processes for producing the polynucleotides and polypeptides.
- Group X, claim(s) 39-41, drawn to isolated polynucleotides and polypeptides related to or encoding SEQ ID NOS:19 and 20 as well as processes for producing the polynucleotides and polypeptides.

The inventions listed as Groups I-X do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The claims of each group are directed to separate and distinct polynucleotide and polypeptide sequences structurally unrelated, each to the other. Therefore, the inventions lack the same or corresponding special technical feature.